Introduction {#s1}
============

DNA methylation is a highly conserved chromatin modification that is associated with gene silencing and plays critical roles in imprinting, transposon repression, and diverse developmental processes in eukaryotic organisms. In *Arabidopsis*, methylated regions of the genome can be separated into two main categories: (1) transposons and repeats that are heavily methylated at cytosines in all sequence contexts (namely CG, CHG and CHH where H indicates A, T or C), leading to gene silencing, and (2) body-methylated genes that harbor methylation exclusively in the CG context but remain highly expressed ([@bib38]; [@bib7]). These global patterns of cytosine methylation reflect a balance between pathways controlling de novo methylation, maintenance methylation and demethylation ([@bib31]; [@bib41]).

De novo methylation of cytosines in all sequence contexts requires the RNA-directed DNA methylation (RdDM) pathway ([@bib31]; [@bib41]), which utilizes both 24-nucleotide small interfering RNAs (24-nt siRNAs) and long non-coding RNAs to target the de novo methyltransferase, DOMAINS REARRANGED METHYLTRANSFERASE 2 (DRM2), to repetitive regions of the genome. Production of both 24-nt siRNAs and non-coding RNAs requires specialized RNA polymerases ([@bib16]; [@bib79]). Pol IV transcripts were recently identified ([@bib4]; [@bib76]; [@bib36]) and these short non-coding RNAs are processed into 24-nt siRNAs in a one precursor, one siRNA fashion ([@bib4]; [@bib76]) and then loaded into the ARGONAUTE 4 (AGO4) clade of effector proteins. Pol V also generates non-coding RNAs at RdDM targets and these RNAs serve as a scaffold for the recruitment of many downstream RdDM factors, including siRNA-loaded AGO4 effector complexes and DRM2, ultimately leading to the deposition of DNA methylation and the establishment of gene silencing.

After the initial establishment of DNA methylation, several maintenance DNA methylation pathways are in place to ensure the faithful inheritance of DNA methylation patterns ([@bib31]; [@bib41]). Briefly, maintenance of CG methylation requires DNA METHYLTRANSFERASE 1 (MET1), whereas maintenance of CHG methylation (and some CHH methylation) relies on the activity of two related DNA methyltransferases, CHROMOMETHYLASE 2 and 3 (CMT2 and CMT3) ([@bib61]; [@bib73]). Finally, the remaining CHH methylation is maintained by DRM2 via the continuous action of the RdDM pathway.

Acting in opposition to the DNA methylation machinery are several DNA glycosylases, REPRESSOR OF SILENCING 1 (ROS1) and three paralogs: DEMETER (DME), DEMETER-LIKE 2 (DML2), and DEMETER-LIKE 3 (DML3). These glycosylases specifically remove methyl-cytosine bases, resulting in a net loss of DNA methylation ([@bib80]). While DME plays an essential role during plant reproduction, ROS1, DML2, and DML3 act in a semi-redundant manner to remove DNA methylation in vegetative tissue ([@bib38]; [@bib80]; [@bib47]). These proteins tend to remove DNA methylation in regions that flank genes, and in *ros1 dml2 dml3* (*rdd*) triple mutants a subset of these genes are silenced, leading to a model in which ROS1, DML2 and DML3 function to remove DNA methylation and prevent transcriptional gene silencing ([@bib38]; [@bib80]; [@bib47]).

Finally, to interpret the patterns of DNA methylation, there are two large families of methyl-DNA binding proteins in plants, both of which are conserved in mammals: the SET AND RING ASSOCIATED (SRA) domain family, and the METHYL-CpG-BINDING domain (MBD) family ([@bib9]; [@bib12]). While specific roles for several SRA domain proteins in the establishment and/or maintenance of DNA methylation in plants and mammals have been determined ([@bib22], [@bib23]; [@bib69]; [@bib5]; [@bib60]), roles for plant MBDs remain largely unknown. In mammals, MBD proteins function as part of large protein complexes associated with histone deacetylase and methyltransferase activities important for the establishment of repressive chromatin states ([@bib24]; [@bib45]; [@bib13]; [@bib77]). In *Arabidopsis*, there are 13 proteins that contain MBD domains (MBD1-13) ([@bib14]; [@bib72]). Of these MBD proteins, early studies demonstrated that MBD5, MBD6 and MBD7 bind methylated DNA in vitro and localize to highly methylated, peri-centromeric regions of the genome in vivo, suggesting roles for these factors in gene silencing ([@bib71]; [@bib56]; [@bib20]; [@bib74]). A better understanding of how the MBD proteins bridge the gap between DNA methylation and gene regulation, however, is just beginning to emerge. For example, MBD6 and MBD10 play roles in nucleolar dominance and rDNA silencing ([@bib50]), whereas MBD7 has been implicated in DNA demethylation based on genetic connections with the DNA demethylase, ROS1 ([@bib28]; [@bib34]; [@bib66]).

Compared to the wealth of mechanistic detail regarding the proteins and pathways required to establish, maintain and even remove DNA methylation, relatively little is known about the events occurring downstream of DNA methylation. Previous genetic screens have identified *MORPHEUS MOLECULE 1* (*MOM1*) ([@bib2]; [@bib68]), and *MICRORCHIDIA 1* and *6* (*MORC1* and *MORC6*) ([@bib43]; [@bib40]; [@bib6]), as genes that are required for the silencing of methylated loci but that do not control the levels of DNA methylation ([@bib2]; [@bib68]; [@bib43]; [@bib40]). In addition, mutations in *ARABIDOPSIS TRITHORAX-RELATED PROTEIN 5* and *6* (*atxr5* and *atxr6*) ([@bib21]) were also found to release gene silencing without significantly altering the pattern of DNA methylation. These findings suggest that there are factors that function downstream (or independently) of DNA methylation to facilitate gene silencing though unknown mechanisms. On the other hand, only one factor, SU(VAR)3--9 HOMOLOG 1 (SUVH1) ([@bib35]), has been identified to act downstream of DNA methylation to enable the transcription of methylated loci.

In the present study, we demonstrate a role for MBD7 and its associated proteins (LOW IN LUCIFERASE EXPRESSION (LIL) and REPRESSOR OF SILENCING 5 (ROS5), two Alpha Crystallin Domain (ACD) proteins, as well as REPRESSOR OF SILENCING 4 (ROS4)), in the suppression of gene silencing at methylated luciferase (*LUC*) reporter transgenes. In addition, we show that MBD5 co-purifies with a distinct set of ACD proteins but, unlike MBD7, is not required for *LUC* expression, suggesting different roles for the MBD5 and MBD7 complexes. To gain mechanistic insights into the role of the MBD7 complex in regulating gene expression, the DNA methylation and *LUC* expression levels at the reporter transgenes were determined in *mbd7*, *lil, ros4* and *ros5* mutants. These analyses revealed that members of the MBD7 complex function to promote luciferase expression without significantly altering DNA methylation levels. Furthermore, genome-wide characterization of DNA methylation patterns in *mbd7, lil*, and *rdd* mutants revealed little to no overlapping changes in DNA methylation. Together, these findings support a role for the MBD7 complex in the suppression of gene silencing that is primarily downstream of DNA methylation. While several proteins have been identified that reinforce gene silencing downstream of DNA methylation, the MBD7 complex is unique in its ability to overcome the silencing effects of DNA methylation, enabling the expression of several transgenes despite high levels of promoter methylation.

Results {#s2}
=======

Characterization of two luciferase (*LUC*)-based transcriptional gene silencing reporters {#s2-1}
-----------------------------------------------------------------------------------------

To identify genes that suppress transcriptional gene silencing in *Arabidopsis*, forward genetic screens were conducted using two *LUC*-based reporters, *LUCH* ([@bib68]) and *YJ* ([@bib35]), that were introduced into the *rdr6-11* mutant background to prevent post-transcriptional silencing. Here we compared the expression patterns and epigenetic features of the two *LUC* reporters, which differ in their basal levels of *LUC* expression despite harboring nearly identical transgenes that contain *LUC* genes driven by dual cauliflower mosaic virus *35S* promoters (*d35S*) ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}, [Figure 1---figure supplements 1A,B](#fig1s1){ref-type="fig"}). Given the known role of DNA methylation in regulating *LUC* expression at the *LUCH* reporter ([@bib68]), the DNA methylation and siRNA profiles for both *LUCH* and *YJ* reporters were determined by MethylC-sequencing (MethylC-seq) and small RNA sequencing (smRNA-seq), respectively ([Supplementary file 1A-D](#SD3-data){ref-type="supplementary-material"}), allowing either multi-mapping ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) or unique reads ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). At the *d35S* promoters, the two transgenes had similar patterns of 24-nt siRNAs and similar levels of DNA methylation in all sequence contexts ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). However, in *LUCH*, DNA methylation extended beyond the *d35S* promoters into the *LUC* and *NPTII* coding regions ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). One possible explanation for the difference in DNA methylation and *LUC* expression between *YJ* and *LUCH* reporters lies in the nature of the transgene insertions. Although both reporters segregate as single-copy insertions, analysis of the MethylC-seq data supports the conclusion that the *YJ* and *LUCH* reporters represent single and multi-copy insertions into a single genomic locus, respectively ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). In addition to their copy number, these transgenes also differ in their integration sites, which may further contribute to their DNA methylation and expression profiles. Despite these differences, both reporters share a common feature that distinguishes them from most endogenous methylated loci: they contain genes that harbor high levels of promoter methylation but are not fully silenced. This feature makes these reporters well suited to screen for proteins that suppress gene silencing at methylated loci.

*LIL* suppresses silencing at two *LUC* reporters {#s2-2}
-------------------------------------------------

To identify factors that suppress gene silencing at the *LUC* reporters, two independent genetic screens using either the *YJ* or the *LUCH* reporter line, were performed. Two mutants with reduced luciferase luminescence, one in each reporter background, were identified ([Figure 1A](#fig1){ref-type="fig"}) and RT-qPCR analysis confirmed reduced *LUC* expression in these mutant backgrounds relative to their respective controls ([Figure 1B](#fig1){ref-type="fig"}). Map-based cloning and candidate gene sequencing revealed that the same gene (*At1g20870*) was disrupted in both mutants. The alleles isolated from the *YJ* and *LUCH* screens are hereafter referred to as *lil-1* and *lil-2 (LIL, [L]{.ul}OW [I]{.ul}N [L]{.ul}UCIFERASE EXPRESSION*), respectively. The *lil-1* allele contains a G-to-A mutation, which disrupts the single splice acceptor site of *At1g20870* ([Figure 1C](#fig1){ref-type="fig"}). Although *lil-2* was isolated from a T-DNA mutagenesis screen, this allele does not contain a T-DNA insertion, but instead contains a C-to-T mutation that introduces a premature stop codon ([Figure 1C](#fig1){ref-type="fig"}). *LIL* is predicted to encode a 51.9 kDa protein containing a carboxy-terminal Alpha Crystallin Domain (ACD) or Heat Shock Protein 20 like (HSP20-like) chaperone domain ([Figure 1C](#fig1){ref-type="fig"}). Among the 25 *Arabidopsis* ACD-containing proteins, LIL and three paralogs form one clade ([@bib57]) (alignments shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Two members of this clade, LIL (also known as INCREASED DNA METHYLATION 3 (IDM3) \[[@bib28]\] or INCREASED DNA METHYLATION 2-LIKE 1 (IDL1) \[[@bib34]\]) and ROS5 ([@bib78])/IDM2 ([@bib52]) (At1g54840) were recently found to prevent DNA hyper-methylation and enable gene expression at other reporter transgenes and select genomic loci, demonstrating they also act to suppress gene silencing ([@bib28]; [@bib34]; [@bib78]; [@bib52]).10.7554/eLife.19893.002Figure 1.LIL promotes expression of methylated LUC reporters.(**A**) Luciferase (LUC) luminescence in *YJ*, *YJ lil-1*, *LUCH* and *LUCH lil-2* seedlings as diagramed on the left. (**B**) Quantification of *LUC* transcript levels by RT-qPCR. Transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from two biological replicates. (**C**) LIL gene structure showing the positions of the two isolated mutations relative to the exons (black bars) and a single intron (black line). Lower and upper case letters represent intron and exon sequences, respectively. The region encoding the conserved ACD or HSP20-like chaperone domain is indicated below.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.002](10.7554/eLife.19893.002)10.7554/eLife.19893.003Figure 1---source data 1.Alignment of the *YJ* and *LUCH* transgenes.Clustal alignment numbered relative to *YJ*. Perfectly matched residues are marked with an asterisk (\*) below the alignment.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.003](10.7554/eLife.19893.003)10.7554/eLife.19893.004Figure 1---figure supplement 1.Characterization of the *LUCH* and *YJ* luciferase (*LUC*) reporter lines.(**A**) LUC luminescence in *LUCH* and *YJ* backgrounds as diagrammed on top. (**B**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* and *LUCH* expression was set to one. Error bars indicate the standard deviation from two biological replicates. (**B**) A diagram of the *LUC* transgenes present in the *LUCH* and *YJ* reporter lines, drawn to scale relative to the browser tracks shown in (**C**). The *LUC* gene and the selectable marker *NPTII* are each driven by a dual *35S* promoter (*d35S*). The right and left borders of the T-DNA are labeled as RB and LB, respectively. The *LUCH* and *YJ* transgenes differ only at the 3' end of the *LUC* gene, with *LUCH* containing a miR172 binding site ([@bib68]) and *YJ* containing a miR173 site ([@bib35]). (**C**) Epigenetic features of the *LUCH* and *YJ* transgenes. DNA methylation tracks show the percent DNA methylation (0--100%) in the CG (green), CHG (blue) and CHH (red) sequence contexts at cytosines covered by at least five reads (H = A, T or C). Coverage tracks (purple) show the number of reads per cytosine mapped to the transgene. Small RNA tracks (orange) show 24-nt siRNAs (transcripts per thousand (K)) mapped to the transgene on the Watson (W) or Crick (C) strands. Note that the *d35S* promoters driving *LUC* and *NPTII* expression are 94% identical in sequence, thus the DNA methylation, siRNA and coverage data for these tracks include both multi-mapping and unique reads. (**D**) Quantification of the average percent methylation across the *d35S* promoter (282--1036) or the *LUC* coding region (1179--2832) in the *LUCH* and *YJ* transgenes presented in (**C**). For each sequence context, the number of cytosines in the quantified regions is indicated in parentheses. (**E**) DNA methylation tracks as in (**C**) but only allowing uniquely mapping reads.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.004](10.7554/eLife.19893.004)10.7554/eLife.19893.005Figure 1---figure supplement 2.Investigation of transgene copy number.(**A**) Diagram of the *At1g02740* gene showing the location of the *YJ* reporter insertion site based on the MethylC-seq reads. Chimeric reads between the *YJ* reporter, in the vicinity of the RB and LB elements, mapped exclusively to the *At1g02740 3'UTR* and are shown above the *At1g02740* gene. A deletion in the *At1g02740 3'UTR* inferred from these same sequences is shown below the *At1g02740* gene. (**B**) Genome browser view showing the results from mapping the MethylC-seq data to the entire binary vector used for the generation of the *YJ* reporter line. The individual reads are shown in grey (lower track) and the total read coverage in purple (upper track). Negligible reads were identified mapping to the plasmid backbone. (**C**) Model showing a single copy insertion of the *YJ* reporter into the *At1g02740 3'UTR*. (**D**) Diagram of the *At3g07350* gene showing the location of the *LUCH* reporter insertion site based on the MethylC-seq reads. Chimeric reads between the *LUCH* reporter, in the vicinity of the RB and LB elements, mapped to several genetic elements. (1) Chimeric reads corresponding to the outermost regions of the insert mapped to the coding sequence of the *At3g07350* gene and are shown above the gene model. A deletion in the *At3g07350* coding sequence inferred from the MethylC-seq data is shown below the *At3g07350* gene. (2) Reads mapping to the *LUCH* reporter that extend beyond the RB into the plasmid backbone were also identified. (3) Finally, chimeric reads consistent with the presence of an *LUCH* inverted repeat, were also present. (**E**) Genome browser view showing the coverage results from mapping the MethylC-seq data to the binary vector used for the generation of the *LUCH* reporter line. Reads spanning nearly the entire plasmid backbone were identified suggesting a non-canonical insertion profile. (**F**) Model of one possible configuration of the *LUCH* reporter that is consistent with the junctions identified in panel (**D**), the presence of the entire binary vector as identified in panel (**E**), and published Southern blot data ([@bib68]). The colors of the sequences and elements are as indicated. Sequences in capital or lower case represent coding and non-coding sequences, respectively. The bold, italic purple sequence in panel (**D**) demarcates the inverted repeat in the vicinity of the *LUCH* LB. In panel (**E**), the read numbers are capped at 50 and regions with \>50 reads are indicated by the presence of a thick black bar above the reads.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.005](10.7554/eLife.19893.005)10.7554/eLife.19893.006Figure 1---figure supplement 3.Sequence alignment of LIL and its paralogs.LIL paralogs were identified using the *Arabidopsis thaliana* WU-BLAST2 Search function using the TAIR10 Proteins dataset and the full-length amino-acid sequence of LIL (At1g20870) as a query (<http://www.arabidopsis.org>). The protein sequences were aligned using ClustalW2 (<http://embnet.vital-it.ch/software/ClustalW.html>) and displayed using Genedoc. Black and grey boxes indicate identical and similar residues, respectively. The region encoding the HSP20-like chaperone domain is indicated by the red line above the alignment. The consensus sequences are indicated underneath the protein alignment.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.006](10.7554/eLife.19893.006)

LIL is associated with MBD7 {#s2-3}
---------------------------

To gain insight into the function of LIL, a yeast two-hybrid (Y2H) screen was conducted to identify LIL-interacting proteins. Using full-length LIL as bait and an *Arabidopsis* cDNA library as prey, LIL was found to interact with three MBD proteins: MBD5, MBD6 and MBD7 ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). To map the interaction domains of these proteins, select subdomains were subjected to additional Y2H assays ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Using either the N-terminal portion of LIL (LILN3) or the ACD/HSP20 domain alone (LILD1), no interactions were observed with the full length MBD proteins ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). However, an interaction was detected between the last MBD domain of MBD7 (MBD7d3) and the full length LIL protein ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Previously, [@bib28] mapped the interaction domain between LIL and MBD7 to the C-terminal sticky-c (StkC) domain ([@bib75]) of MBD7 and found that the three MBD domains of MBD7 alone were not sufficient to mediate an interaction with LIL. However, the MBD7d3 construct used here represents an extended version of the third MBD domain that has minimal overlap with the StkC domain, suggesting that the interaction between MBD7 and LIL can be mediated by several regions of the MBD7 protein, namely, the StkC domain ([@bib28]), as well as the last MBD domain ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}).

In a parallel effort, epitope-tagged versions of MBD5 and MBD7, expressed under the control of their endogenous promoters, were affinity purified and found to associate with distinct sets of ACD domain proteins by Mass Spectrometry ([Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}). Specifically, a 3x-Flag-tagged version of MBD5 (*pMBD5::MBD5-3x-Flag*) was shown to co-purify with ACD15.5 (At1g76440) and ACD21.4 (At1g54850) as well as low amounts of MBD6 ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), while purification of a 3x-HA tagged version of MBD7 (*pMBD7::MBD7-3xHA*) revealed a specific interaction with LIL ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). As MBD7 had previously been shown to also associate with ROS4, ROS5 ([@bib28]; [@bib34]; [@bib66]), and HARBINGER TRANSPOSON-DERIVED PROTEIN 1 (HDP1) and HDP2 ([@bib10]), additional purifications using a 3x-Flag-tagged version of MBD7 (*pMBD7::MBD7-3xFlag*) were conducted and these experiments yielded peptides corresponding to LIL as well as all the aforementioned MBD7-associated proteins ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). Taken together, these findings demonstrate that MBD5 and MBD7 associate with different subsets of ACD proteins to form distinct MBD-ACD protein complexes, the roles and compositions of which are just beginning to be explored.

*MBD7*--associated factors suppress silencing at the *LUC* reporter {#s2-4}
-------------------------------------------------------------------

To determine the roles of the MBD5 and MBD7 complexes in the regulation of gene expression, mutant alleles in the various components were obtained ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) and their effect on *LUC* expression was determined. For these experiments, two alleles of *ROS4* (*ros4-2* and *ros4-*3) were recovered from the *YJ* reporter screen and the following additional mutant lines were crossed into the *YJ* reporter background in either the Col or L*er* ecotypes (see Materials and methods): *mbd5-1, mbd5-3*, *mbd7-3, mbd7-4, mbd7-5*, and *ros5-4*. The *mbd5* mutations had no effect on *LUC* expression at the *YJ* reporter ([Figure 2---figure supplement 3A,B](#fig2s3){ref-type="fig"}). Conversely, in the *mbd7*, *ros4*, and *ros5* mutants, *LUC* expression was reduced to similar levels as observed in *lil-1* ([Figure 2A,B](#fig2){ref-type="fig"}). In addition, expression of the *d35S-*driven *NPTII* gene present in both *YJ* and *LUCH* reporters was also reduced in these mutants ([Figure 2C](#fig2){ref-type="fig"}). These findings are consistent with the co-purification of these factors by Mass Spectrometry and demonstrate a role for the MBD7 complex, but not MBD5, in promoting the expression of the *LUC* reporter.10.7554/eLife.19893.007Figure 2.*mbd7*, *ros4*, and *ros5* mutants phenocopy *lil-1* at the YJ transgene.(**A**) Luciferase (LUC) luminescence in 10-day-old seedlings as diagramed on the left. (**B**) Quantification of *LUC* or (**C**) *NPTII* transcript levels by RT-qPCR. Transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* or *NPTII* in the *YJ* or *LUCH* controls set to one. Error bars indicate the standard deviation from two biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.007](10.7554/eLife.19893.007)10.7554/eLife.19893.008Figure 2---figure supplement 1.Yeast two-hybrid and affinity purification analyses.(**A**) Diagrams of the yeast two-hybrid constructs used in (**B**). Full-length or partial fragments of LIL or MBD proteins were fused to the GAL4 DNA binding domain (BD) or the GAL4 activation domain (AD) sequences, respectively. The black box indicates the region of LIL encoding the ACD/HSP20-like chaperone domain. Grey boxes indicate methyl-CpG-binding domains. The green bar corresponds to the StkC region of MBD7. aa, amino acid. (**B**) Yeast two-hybrid interactions. LIL-BD and MBD-AD plasmids were co-transformed into the yeast strain AH109. Yeast growth on -Trp/-Leu plates confirms the transformation of both plasmids into yeast. Yeast growth on -Trp/-Leu/-Ade/-His plates indicates protein interactions. (**C**) Table of proteins that specifically co-purify with MBD7 following HA or Flag affinity purification and MudPit Mass Spectrometry from two biological replicates (rep_1 and rep_2) or a single purification (rep1), respectively. (**D**) Table of proteins that specifically co-purify with MBD5 following Flag affinity purification and MudPit Mass Spectrometry from three biological replicates (rep_1, rep_2 and rep_3). In (**C**) and (**D**), affinity purifications were conducted using protein extracted from transgenic plants expressing either MBD7-3xHA, MBD7-3xFlag (**C**) or MBD5-3xFlag (**D**) and non-transgenic plants of the Col ecotype as a negative control. Values shown are the normalized spectral abundance factors (NSAF) ([@bib11]).**DOI:** [http://dx.doi.org/10.7554/eLife.19893.008](10.7554/eLife.19893.008)10.7554/eLife.19893.009Figure 2---figure supplement 2.Isolation and characterization of *ros4*, *mbd5*, *mbd7*, and *ros5* mutants.(**A**) Schematic diagram showing the positions of the two mutations in the *ROS4* gene isolated in the *YJ* screen. Both the *ros4-2* and *ros4-3* alleles contain G-to-A mutations that result in the generation of stop codons at amino acids 988 and 763, respectively. (**B--D**) Schematic diagrams showing the sites of the *mbd5* (**B**), *mbd7* (**C**), and *ros5* (**D**) T-DNA insertions (inverted green triangles) and genome browser tracks (Sashimi plots; <https://software.broadinstitute.org/software/igv/Sashimi>) showing the mRNA sequencing reads mapping to these genes. Genotypes (upper left) and data ranges (left) are indicated for each track. Chevron symbols indicate the direction of the gene, the thick and thin black boxes represent the exons and UTRs, respectively, and the black lines represent introns. The lines connecting the exons are labeled with the number of reads supporting splice junctions. The methyl-CpG-binding domains (MBDs), alpha crystallin domain (ACD), plant homeodomain (PHD), and histone acetyltransferase domains (HAT) are indicated in grey above the diagrams.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.009](10.7554/eLife.19893.009)10.7554/eLife.19893.010Figure 2---figure supplement 3.*mbd5* mutants do not exhibit reduced *LUC* expression.(**A**) Luciferase (LUC) luminescence in 10-day-old seedlings as diagramed on the left. (**B**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from two biological replicates. '*mbd5-sib\#*' represent sibling plant lines of the indicated T-DNA mutant allele.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.010](10.7554/eLife.19893.010)

The MBD7-LIL complex regulates *LUC* expression at the transcriptional level {#s2-5}
----------------------------------------------------------------------------

Previous analyses have shown that both the *YJ* ([@bib35]) and *LUCH* ([@bib68]) reporters are regulated by DNA methylation such that treatment with the cytosine methylation inhibitor 5-aza-2'-deoxycytidine (5-Aza-dC) results in increased *LUC* expression. To determine if DNA methylation is necessary for the phenotypes observed upon disruption of the MBD7 complex, we assessed the effects of 5-Aza-dC treatment on *LUC* expression in several alleles of *lil* and *mbd7* and found the levels of *LUC* expression in these mutants were indistinguishable from their respective controls ([Figure 3A,B](#fig3){ref-type="fig"}). Thus, LIL and MBD7 are only necessary for the expression of the *LUC* reporters when they harbor DNA methylation, affirming their roles in the transcriptional, rather than post-transcriptional, regulation of *LUC* expression.10.7554/eLife.19893.011Figure 3.MBD7 and LIL regulate *LUC* expression in a DNA methylation-dependent manner.(**A**) Luciferase luminescence of mock or 5-aza-2'-deoxycytidine (5-Aza-dC)-treated seedlings as diagramed on the left. (**B**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from three biological replicates for the *mbd7* datasets and three technical replicates for the *lil* dataset.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.011](10.7554/eLife.19893.011)

Disruption of the MBD7 complex results in minimal effects on DNA methylation at the *LUC* reporters {#s2-6}
---------------------------------------------------------------------------------------------------

To determine whether the decreased *LUC* expression observed upon disruption of the MBD7 complex is associated with an increase in DNA methylation, methyl-DNA cutting assays and MethylC-seq experiments were conducted. For the methylation cutting assays, genomic DNA was either mock treated or digested with the McrBC restriction enzyme followed by PCR amplification. Since McrBC specifically cuts methylated DNA, hyper-methylated targets are expected to exhibit reduced levels of PCR amplification. Using this assay, amplification of the *d35S* promoter was reduced in both *lil* mutants relative to their respective controls, indicating that mutations in *LIL* increased the level of DNA methylation at the *d35S* promoter ([Figure 4A](#fig4){ref-type="fig"}; gel based). Similar results were obtained for *lil-1, mbd7*, *ros4*, and *ros5* mutants when qPCR was performed to quantify DNA levels from mock or McrBC treated samples ([Figure 4B](#fig4){ref-type="fig"}; qPCR). Together, these analyses reveal a correlation between disruption of the MBD7 complex and an increase in DNA methylation at the *d35S* promoter driving *LUC* expression, but they do not reveal the location or extent of hyper-methylation.10.7554/eLife.19893.012Figure 4.Disruption of the MBD7 complex results in subtle, but reproducible hyper-methylation at the *d35S* promoter.Cytosine methylation analysis by McrBC-PCR (**A**) and McrBC-qPCR (**B**) using mock or McrBC treated genomic DNA from the indicated genotypes. In (**A**), two tandem copies of the *35S* sequence result in two PCR bands. *ACTIN1*, which lacks methylation, was used as the internal loading control. In (**B**), the relative methylation levels are plotted and the error bars indicate the standard deviation from two biological replicates. (**C**) A diagram of the *YJ* reporter drawn to scale relative to the browser tracks shown directly below. The light blue box indicates the region amplified for the McrBC assay. This region is expanded in the far right panel. DNA methylation tracks show the DNA methylation level (0--1, where 1 = 100% methylated) in the CG (green), CHG (blue), and CHH (red) sequence contexts at cytosines covered by at least five reads. The *LUCH_r2* and *YJ_r1* tracks correspond to those shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}. The *YJ mbd7-5 + pMBD7::MBD7-3xHA_r6* (Ler) line corresponds to the 'ins1a' line characterized in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. The coverage track for *mbd7-5_r6* (bottom) shows the number of reads (*y*-axis) mapped to the transgene, demonstrating that sequence homology between the T-DNA in the *mbd7-5* mutant and the LUC reporter is largely limited to the *NPTII* drug resistance gene. To facilitate visual assessment of the changes in DNA methylation, dashed horizontal lines are set relative to the maximal CG methylation at the 3' end of the *d35S* promoter in the control *LUCH* and *YJ* reporters. (**D**) Quantification of the average percent methylation across the entire *d35S* promoter (282--1036), the Full McrBC region (923--1318) or a Short MrcBC region (923--1004) within the *YJ* transgene in the lines presented in (**C**). Each sample is appended with an 'r\#' to indicate samples that were processed and sequenced together. Identical genotypes with different r\#'s indicate biological replicates (e.g., *YJ_r1*, *YJ_r2*, and *YJ_r5* are biological replicates). The number of cytosines in each sequence context within the quantified regions is indicated in parentheses. Note that the two *d35S* promoters driving *LUC* and *NPTII* are 94% identical in sequences, thus the DNA methylation data includes both multi-mapping and unique reads. (**E**) ChIP-qPCR showing enrichment of MBD7-GFP at the *d35S* promoter driving *LUC* expression at the *YJ* reporter. The data represents the average enrichment from three biological replicates as a percentage of the input and the error bars represent the standard deviation between replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.012](10.7554/eLife.19893.012)10.7554/eLife.19893.013Figure 4---figure supplement 1.Complementation of the *mbd7-5* phenotype with MBD7-3xHA.(**A**) Luciferase luminescence in *YJ*, *YJ mbd7-5*, and *YJ mbd7-5 MBD7-3xHA* seedlings as diagramed on the left. Ins \# indicates independent, single-locus insertion lines tested. (**B**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from two biological replicates. (**C**) Western blot showing the relative abundance of the MBD7-3xHA protein in each complementing line. (\*) indicates a non-specific background protein that served as an internal loading control. (**D**) Cytosine methylation analysis by McrBC-qPCR. Genomic DNA was treated with McrBC or mock treated in parallel reactions prior to qPCR amplification of the *d35S* promoter region of the *LUC* gene. *ACTIN1*, which lacks methylation, was used as the internal negative control. Error bars indicate the standard deviation from two biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.013](10.7554/eLife.19893.013)

To quantitatively determine the changes in methylation occurring across the entirety of the *LUC* reporters upon disruption of the MBD7 complex, the patterns of DNA methylation were determined at single nucleotide resolution by bisulfite sequencing using the MethylC-seq method ([@bib65]) in *mbd7* and *lil* mutants ([Supplementary file 1A, 1B and 1E](#SD3-data){ref-type="supplementary-material"}). These transgene analyses were limited to the *lil-1* and *lil-2* alleles, which are point mutations, and the *mbd7-5* allele, which is the only *mbd7* allele where the T-DNA insertion does not share sequence homology with the *d35S* promoters present in the *LUC* reporters ([Figure 4C](#fig4){ref-type="fig"}, see 'no *YJ* transgene control tracks'). At the *LUC* reporters, quantification of the average methylation levels across the *d35S* promoter (282--1036 nt) revealed a surprisingly modest but consistent increase in DNA methylation in the CG context in *lil-2*, *mbd7-5,* and three biological replicates of *lil-1* ([Figure 4D](#fig4){ref-type="fig"}). Further inspection of the DNA methylation profiles revealed that this hyper-methylation is largely restricted to a small region at the 3' end of the *d35S* promoter, which is within the region amplified in the McrBC-PCR methyl-cutting assays ([Figure 4C](#fig4){ref-type="fig"}; right panels). Quantification of DNA methylation at this region was assessed either in its entirety (923--1318), to best evaluate the change in methylation at the *LUCH* reporter, or in a more limited region (923--1004) that encompasses most of the methylation observed in the *YJ* reporter. In the *lil-2* mutant, a slight increase in CG and CHG methylation, but no change in CHH methylation, was observed at the *LUCH* reporter ([Figure 4D](#fig4){ref-type="fig"}; Full McrBC). For the *lil-1* replicates and *mbd7-5*, a more prominent increase in CG and CHG methylation was observed, and these DNA methylation defects were significantly reversed by introduction of an *MBD7-3xHA* construct that rescues the *LUC* expression phenotype at the *YJ* reporter ([Figure 4D](#fig4){ref-type="fig"} short McrBC and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}, respectively). As these findings reveal a correlation between the presence of a functional MBD7 complex and the DNA methylation status of the *YJ* reporter, several chromatin immunoprecipitation (ChIP) experiments were conducted to determine whether the MBD7 complex associates with this reporter. While no enrichment was observed with either the 3xHA or 3xFlag tagged MBD7 proteins expressed under their native promoters, enrichment was observed at the *d35S* promoter using a previously characterized MBD7-GFP line driven by a *35S* promoter ([@bib66]) ([Figure 4E](#fig4){ref-type="fig"}). Taken together, these methylation and ChIP analyses are consistent with the hyper-methylation phenotype observed in the methyl-cutting assays and suggest a direct role for the MBD7 complex in regulating expression at the *YJ* reporter.

Genetic uncoupling of the hyper-methylation and *LUC* expression phenotypes at the *YJ* reporter {#s2-7}
------------------------------------------------------------------------------------------------

Given the limited changes in DNA methylation observed at the *LUC* reporters in the *lil* and *mbd7* mutants (especially compared to the striking reduction in *LUC* expression), we sought to better understand how alterations in DNA methylation influence *LUC* expression at the *YJ* reporter. We therefore manipulated the methylation pattern of the *d35S* promoter using known DNA methylation mutants and then assessed the effect on *LUC* expression. We chose two strong RNA-directed DNA methylation (RdDM) mutants, *ago4* and *nrpe1*, and the triple demethylase mutant, *rdd*. Unfortunately, the T-DNAs in these mutants have significant sequence homology with the *d35S* promoter in the *YJ* transgene ([Supplementary file 1A](#SD3-data){ref-type="supplementary-material"}). Thus, to specifically assess DNA methylation at the *d35S* promoter driving the *LUC* gene, without interference from the 94% identical *d35S* promoter driving *NPTII* expression (Figure 1---figure supplement 1C,E) or the similar *d35S* promoters present in the T-DNA insertion mutant backgrounds, traditional bisulfite conversion assays coupled with Sanger sequencing were conducted. For comparison, a full set of alleles in the Col ecotype (*lil-1*, *mbd7-4*, *ago4-6*, *nrpe1-11*, and *rdd*) and the complementation data set in the L*er* ecotype, all in the *YJ rdr6-11* background, were included.

First, we compared results from traditional bisulfite sequencing in the *lil* and *mbd7* mutants with those from MethylC-seq. The DNA methylation levels observed at the *35S* promoter by traditional bisulfite sequencing are represented in browser track format ([Figure 5A](#fig5){ref-type="fig"} and [Supplementary file 1D](#SD3-data){ref-type="supplementary-material"}: YJ_tradBS_WigTracks) and show similar patterns of methylation in the *lil* and *mbd7* mutants when compared to the MethylC-seq data ([Figure 4C,D](#fig4){ref-type="fig"}), in that hyper-methylation (primarily in the CG and CHG contexts) was detected at the 3' end of the promoter ([Figure 5A,B](#fig5){ref-type="fig"}). Also consistent with the MethylC-seq data, the increased methylation observed in the *mbd7-5* mutant was restored to a more wild-type level upon introduction of the *pMBD7::MBD7-3xHA* transgene ([Figure 5A,B](#fig5){ref-type="fig"}). These findings demonstrate that the two methods of bisulfite sequencing gave similar results. However, unlike the MethylC-seq data ([Figure 1---figure supplement 1C,E](#fig1s1){ref-type="fig"}), the traditional bisulfite sequencing definitively shows that the changes in DNA methylation observed in the *lil* and *mbd7* mutants occur at the *35S* promoter driving *LUC* expression. Furthermore, the traditional bisulfite sequencing offers the added benefit of determining whether the average percent methylation across the *35S* promoter represents a uniform distribution of methylation or a bimodal distribution (i.e., some promoters showing high methylation levels and others showing low methylation levels). These analyses revealed a uniform distribution of methylation at the *YJ* reporter ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Thus, it does not appear that there is a significant population of fully unmethylated (or even specifically 3' unmethylated) *35S* promoters that give rise to the observed *LUC* expression.10.7554/eLife.19893.014Figure 5.Genetic uncoupling of the DNA methylation and *LUC* expression phenotypes at the *YJ* reporter.(**A**) Diagram of the *YJ* transgene indicating the region examined by traditional bisulfite sequencing (631--1004). DNA methylation tracks show the DNA methylation level (0--1, where 1 = 100% methylated) in the CG (green), CHG (blue) and CHH (red) sequence contexts. The tracks represent the average methylation at each position. The number of clones per genotype is indicated in parentheses to the left of each track. The orange bars below the methylation tracks denote regions that produce 24-nt siRNA clusters. The dashed horizontal lines spanning the methylation tracks are set relative to the maximal CG methylation at the 3' end of the *d35S* promoter in the *YJ* reporter to facilitate visual assessment of the changes in DNA methylation in the mutant backgrounds. (**B**) Quantification of the average percent methylation across the second *35S* promoter (631--1004) or a shorter region at the 3' end of the *35S* promoter (923--1004) within the *YJ* transgene in the lines presented in (**A**). The number of cytosines in each sequence context within the quantified regions is indicated in parentheses. Note that these numbers differ from those presented in [Figure 4](#fig4){ref-type="fig"} since the traditional bisulfite sequencing only captures methylation on one strand. (**C**) Luciferase luminescence of 10-day-old seedlings as diagramed on the left. (**D**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from two biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.014](10.7554/eLife.19893.014)10.7554/eLife.19893.015Figure 5---figure supplement 1.Traditional bisulfite sequencing at the *YJ* reporter.CyMATE ([@bib19]) alignments showing the methylation patterns at the 3' half of the dual *35S* promoter driving *LUC* expression in the *YJ* reporter. For each sample set, the genotypes are indicated on the left and the reference sequence is shown in grey. Methylated (filled) or unmethylated (open) cytosines are shown for each C in the CG (green circles), CHG (blue squares) and CHH (red triangles) contexts. The region hyper-methylated in the *mbd7*, *lil* and *rdd* mutants is shown in red above the alignment. Missing symbols indicate ambiguities in the sequencing results.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.015](10.7554/eLife.19893.015)

We next determined the DNA methylation patterns and *LUC* expression levels at the *YJ* reporter in mutants affecting de novo DNA methylation (*ago4* and *nrpe1*) or DNA demethylation (the triple demethylase mutant, *rdd*). These analyses suggest that the hyper-methylation at the 3' end of the *d35S* promoter and *LUC* silencing phenotypes can be genetically uncoupled. At the level of DNA methylation, decreases in non-CG methylation were observed in the *ago4-6* and *nrpe1-11* mutants predominantly at regions of the promoter producing large amounts of 24-nt siRNAs, as predicted for components of the RNA-directed DNA methylation pathway ([Figure 5A](#fig5){ref-type="fig"}; '24-nt siRNA clusters'). Conversely, all three mutants (*ago4-6*, *nrpe1-11* and *rdd*) showed a hyper-methylation phenotype similar to that observed in the *lil* and *mbd7* mutants at the 3' end of the *35S* promoter ([Figure 5A,B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). These findings are consistent with: (1) previously identified genetic connections between LIL, MBD7 and ROS1 ([@bib28]; [@bib34]; [@bib66]; [@bib68]), and (2) studies showing that mutants affecting the establishment of DNA methylation (including *ago4* and *nrpe1*) cause down-regulation of *ROS1* ([@bib17]) via a methylation sensor element in the *ROS1* promoter ([@bib67]; [@bib33]). Notably, although the *ago4-6*, *nrpe1-11* and *rdd* mutants exhibit similar hyper-methylation phenotypes in the CG and CHG contexts at the 3' end of the *35S* promoter, *LUC* expression is much higher in the *ago4* and *nrpe1* mutants than in the *rdd* mutant ([Figure 5C,D](#fig5){ref-type="fig"}). While compensatory effects on gene expression due to decreased non-CG methylation at other regions of the *d35S* promoter in the *ago4* and *nrpe1* mutants cannot be fully excluded, these findings suggest that the hyper-methylation at the 3' end of the *d35S* promoter region alone is not sufficient to cause gene silencing. Taken together, these analyses reveal that at the *YJ* reporter the MBD7 complex can regulate gene expression in a manner that is largely downstream of DNA methylation.

Genome-wide profiling shows that *mbd7* and *lil* mutants have minimal effects on DNA methylation {#s2-8}
-------------------------------------------------------------------------------------------------

To investigate the role of the MBD7 complex in regulating DNA methylation and to further characterize the relationship between this protein complex and other pathways known to regulate DNA methylation, bisulfite sequencing experiments were conducted. Specifically, the MethylC-seq method ([@bib65]) was employed to determine the methylation profiles of paired sets of mutant and control lines at an average of \~30x coverage with ≥97% conversion rates ([Supplementary file 1E and 1F](#SD3-data){ref-type="supplementary-material"}). Altogether, methylation was profiled in two alleles of *LIL* (*lil-1* and *lil-2* in the *YJ* and *LUCH* backgrounds, respectively), two alleles of *MBD7* (*mbd7-3* and *mbd7-4*, both in the *YJ* background), and the triple DNA demethylase mutant (*rdd* introgressed into the Col background ([@bib47])). In addition, three biological replicates of *lil-1* (*lil-1*\_r1, *lil-1*\_r2, and *lil-1*\_r5), each with their own controls, were profiled ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}). Using this MethylC-seq data, differentially methylated regions (DMRs) were called using methods very similar to those described in [@bib62]. In both DMR calling pipelines, an initial set of DMRs were called using the same requirements: an absolute change in methylation of ≥40% for CG, ≥20% for CHG, and ≥10% for CHH with an FDR \< 0.01 between the mutant and control samples across 100 bp, non-overlapping regions of the genome. However, the two methods used analogous, though not identical, approaches to account for natural variation in DNA methylation, which is known to occur even amongst siblings of the same ecotype ([@bib59]; [@bib3]). While [@bib62] sequenced three biological replicates of a wild-type sample and only included DMRs observed between a given mutant and all three wild-type controls, we instead included a control sample for each biological replicate and/or each mutant allele and then only included DMRs conserved between these replicates. Although thousands of DMRs were identified in each of the *lil-1* and *mbd7* datasets, mostly in the CG and CHH contexts ([Supplementary file 2A](#SD4-data){ref-type="supplementary-material"}), the vast majority of these DMRs were not in common between the different alleles or even between biological replicates ([Supplementary file 2B-F](#SD4-data){ref-type="supplementary-material"}, see orange highlighted comparisons). Indeed, when the DMRs from the three *lil-1* replicates were compared with the DMRs identified in *lil-2*, *mbd7-3* and *mbd7-4*, only 33 hyper and one hypo DMRs remained ([Figure 6A](#fig6){ref-type="fig"}, [Supplementary file 2F](#SD4-data){ref-type="supplementary-material"}; 6-way DMR overlaps, and [Supplementary file 2G-J](#SD4-data){ref-type="supplementary-material"}), and these regions converged on 20 loci (19 displayed hyper-methylation and one showed hypo-methylation \[[Figure 6B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}\]). Thus, while numerous DMRs can be identified between any single *mbd7* or *lil* mutant vs. control ([Supplementary file 2A](#SD4-data){ref-type="supplementary-material"}), very few genomic targets show consistent changes in DNA methylation upon disruption of the MBD7 complex, indicating that these changes may represent natural variation in methylation.10.7554/eLife.19893.016Figure 6.Genomic DMRs identified in the *lil* and *mbd7* mutants.(**A**) Table summarizing DMRs that overlap among all the *lil* and *mbd7* datasets '6-way Direct DMR overlaps'. (**B**) Screenshots showing the DNA methylation levels (0--1, where 1 = 100% methylated, with CG, CHG and CHH contexts in green, blue and red, respectively) at several DMRs in the genotypes indicated on the left. Below the DNA methylation tracks are the following additional features: (1) hyper-variable DMRs in the CG and non-CG contexts from [@bib59], (2) hyper DMRs in the CG, CHG and CHH contexts that overlap amongst all the *lil* and *mbd7* datasets ('Direct DMR overlaps'), (3) an expanded set of DMRs identified as detailed in (**C**) and in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} ('Relaxed DMR overlaps'), (4) body methylated genes as described in [@bib64], and (5) TAIR10 annotated genes and repeats. The percent methylation over each DMR is quantified in the bar graphs below. The average levels of methylation in controls vs. the *mbd7* and *lil* DMRs are shown in black and grey, respectively. The error bars represent the standard deviation to capture the level of variation between samples. The levels of methylation in the MycLIL complementation data set are also indicted. (**C**) Heatmaps showing the methylation levels at DMRs called using a relaxed set of criteria (e.g., DMRs where all of the samples show hyper-methylation in the CHG context, but some are slightly below the required 20% change cutoff). The hyper DMRs are ranked from most to least robust and changes in methylation ≥0.6, ≥0.4, ≥0.3, ≥0.2 and≥0.1 are indicated. The DMRs indicated in panel A ('6-way_Direct DMRs') and the less stringent DMRs that map to genomic regions adjacent to the direct DMRs ('adj. DMRs') are demarcated by black boxes on the heatmaps. (**D**) Venn diagram showing the hyper mC DMRs (see Materials and methods) shared between the *mbd7* and *lil* mutants (red) that overlap with DMRs identified in the *rdd* triple mutant (purple).**DOI:** [http://dx.doi.org/10.7554/eLife.19893.016](10.7554/eLife.19893.016)10.7554/eLife.19893.017Figure 6---figure supplement 1.Visualization and quantification of DNA methylation at the direct overlap DMRs.Screenshots showing the DNA methylation levels (0--1, where 1 = 100% methylated with CG, CHG and CHH contexts in green, blue and red, respectively) at several DMRs in the genotypes indicated on the left. Below the methylated regions are tracks showing the following additional features: (1) hyper-variable DMRs in the CG and non-CG contexts from [@bib59], (2) hyper DMRs in the CG, CHG and CHH contexts that overlap amongst all the *lil* and *mbd7* datasets ('Direct DMR overlaps'), (3) an expanded set of DMRs identified as detailed in [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} ('Relaxed DMR overlaps'), (4) body methylated genes as described in [@bib64], and (5) TAIR10 annotated genes and repeats. The percent methylation over each DMR is quantified in the bar graphs below. The average levels of methylation in controls versus the *mbd7* and *lil* DMRs are shown in black and grey, respectively. The error bars represent the standard deviation to capture the level of variation between samples. The levels of methylation in the *MycLIL* complementation data set are also indicted. DMRs that show a consistent decrease in DNA methylation upon re-introduction of a functional LIL protein that falls significantly outside the levels of variation shown within the *mbd7* and *lil* mutants are marked with an asterisk (\*).**DOI:** [http://dx.doi.org/10.7554/eLife.19893.017](10.7554/eLife.19893.017)10.7554/eLife.19893.018Figure 6---figure supplement 2.Identification of a more relaxed set of DMRs conserved amongst the *mbd7* and *lil* datasets.(**A**) A complete set of all DMRs called in each context (hyper or hypo CG, CHG and CHH) amongst all the *mbd7* and *lil* alleles and biological replicates were compiled and the levels of DNA methylation at these DMRs were calculated and clustered as shown in the six heatmaps. The levels of DNA methylation in each 100 bp region are indicated in the legend on the right. Clusters that behaved similarly across all samples (without imposing fold change or coverage cut-offs) are highlighted in dark pink and represent the set of 'relaxed DMRs'. The number of DMRs in the highlighted region, as well as the fraction of the total DMRs these relaxed DMRs represent, is indicted above the clustering tree. In cases where the selected cluster is too small to visualize, an expanded view is shown below. (**B**) Table showing a comparison of the direct and relaxed DMRs. Hyper and hypo CG regions that overlap with body methylated genes ([@bib64]) are indicated. (**C**) Heatmaps showing the levels of DNA methylation in each sequence context at the identified DMRs. These heatmaps are ranked and labeled as described in [Figure 6](#fig6){ref-type="fig"} and colored as indicated in (**A**). (**D**) Chromosome views showing the locations of hyper DMRs in each sequence context (CG, green; CHG blue; and CHH, red). The DMRs are shown as expanded views on the right to highlight 100 bp DMRs that cluster together. The view on the left shows the chromosomal distribution of all the DMRs regardless of context. \*indicates that DMRs of the same methylation context within 300 bp of each other were merged. \*\*indicates that directly adjacent DMRs, regardless of the methylation context, were merged.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.018](10.7554/eLife.19893.018)10.7554/eLife.19893.019Figure 6---figure supplement 3.Complementation of the *lil-1* phenotype with 9xMyc-LIL.(**A**) Luciferase (LUC) luminescence in *YJ*, *YJ lil-1*, and *YJ lil-1 9xMyc-LIL* seedlings as diagramed on the left. Two sibling, homozygous lines from the same single locus insertion event were analyzed (9xMyc_1 and 9xMyc_2). (**B**) Quantification of *LUC* transcript levels by RT-qPCR. *LUC* transcript levels were normalized to *UBIQUITIN5* with the expression level of *LUC* in the *YJ* control set to one. Error bars indicate the standard deviation from two biological replicates. (**C**) A diagram of the transgene in the *YJ* reporter drawn to scale relative to browser tracks shown directly below. The region amplified for the McrBC assay is highlighted by the light blue box. DNA methylation tracks show the DNA methylation level (0--1, where 1 = 100% methylated) in the CG (green), CHG (blue), and CHH (red) sequence contexts at cytosines covered by at least five reads. The Short McrBC region is expanded in the far right panel. The dashed horizontal lines spanning these methylation tracks are set relative to the maximal CG methylation at the 3' end of the *d35S* promoter in the *YJ* control to facilitate visual assessment of the changes in DNA methylation in the mutant backgrounds. Coverage tracks for all four genotypes are shown below. Regions of the *YJ* transgene that share homology with the transgene harboring the *pLIL::9xMyc-LIL* construct are underlined in black and are outside of the coverage scale (0--50 reads). Notably, these regions fall outside of the *d35S* promoters being assessed for changes in DNA methylation. (**D**) Quantification of the average percent methylation across the *d35S* promoter (282--1036), the Full McrBC region (923--1318) or a shorter MrcBC region (923--1004) within the *YJ* transgene in the lines presented in (**C**). The genotype of each sample is appended with an 'r\#' to indicate samples that were processed and sequenced together. The number of cytosines in each sequence context within the quantified regions in (**D**) is indicated in parentheses. Note that the two *d35S* promoters driving *LUC* and *NPTII* are 94% identical in sequences, thus the DNA methylation data shown includes both multi-mapping and unique reads.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.019](10.7554/eLife.19893.019)10.7554/eLife.19893.020Figure 6---figure supplement 4.Gene expression at previously characterized loci in *mbd7* and *lil* mutants.(**A**) Normalized expression values (FPKM; fragments per kilobase mapped) of control and mutant RNA-seq samples at genes previously shown to be associated with hyper DMRs and to display reduced expression by qPCR in mutants of the MBD7 complex ([@bib28]; [@bib34]; [@bib52]; [@bib10]; [@bib53]). Genes marked by an 'a' were assessed in [@bib28], 'b' in [@bib52], 'c' in [@bib53], 'd' in [@bib10] and 'e' in [@bib34] and the two genes marked by a '\^\' were assayed under heat stress conditions in [@bib28]. The asterisk (\*) marks the only gene consistently down-regulated (\>2x) in any of the mutants tested.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.020](10.7554/eLife.19893.020)

Acknowledging that requiring a direct overlap in DMRs between all six samples is quite stringent, a more relaxed set of DMRs was generated to determine whether a larger number of genomic targets dependent on the MBD7 complex would emerge. For these analyses, the methylation levels across the totality of DMRs identified in any of the various *lil* and *mbd7* mutants were first determined ([Supplementary file 2K-P](#SD4-data){ref-type="supplementary-material"}; MasterDMRLists). DMRs that behaved similarly in all samples were then identified via a clustering analysis and filtered to remove body-methylated genes, which as a group are known to display a higher degree of natural variation in DNA methylation levels ([@bib59]) ([Supplementary file 2Q-U](#SD4-data){ref-type="supplementary-material"}; Relaxed_DMR_lists and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). This yielded a set of 194 CG hyper DMRs, 310 CHG hyper DMRs and 52 CHH hyper DMRs ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). Notably, many of these hyper DMRs are located adjacent to the original set of 33 high stringency DMRs ([Figure 6C](#fig6){ref-type="fig"}; high stringency DMRs from [Figure 6A](#fig6){ref-type="fig"} and DMRs located adjacent to these regions are indicated with black bars in the heatmaps). This demonstrates that both methodologies are converging on a similar, small set of genomic loci that are hyper-methylated in both *mbd7* and *lil* mutants. When changes in methylation regardless of the sequence context were combined, these DMRs converged on 323 genomic regions that are distributed across the five chromosome arms ([Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"} and [Supplementary file 2V and 2W](#SD4-data){ref-type="supplementary-material"}; hyper_mC_merged). Notably, only a third of these regions overlap with regions hyper-methylated in the *rdd* mutant background, representing a tiny fraction of the total *rdd* targets ([Figure 6D](#fig6){ref-type="fig"}). Thus, although there are clear genetic connections between MBD7, LIL and ROS1 in the regulation of several transgenic reporters ([@bib28]; [@bib34]; [@bib66]), as a general rule, the demethylation pathway does not appear to function in a manner that depends solely on either MBD7 or LIL.

To further investigate the functional relevance of the *mbd7* and *lil* hyper DMRs, we determined whether the observed increases in DNA methylation could be complemented by re-introduction of a functional LIL protein. Using stable transgenic plant lines expressing an N-terminal Myc-tagged LIL protein under the control of its endogenous promoter (*pLIL::9xMyc-LIL*), complementation was first confirmed by assessing the *LUC* expression and DNA methylation phenotypes at the *YJ* reporter ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). Then, the global patterns of DNA methylation in the *YJ_r7* and *YJ lil-1_r7* parental lines, as well as two sibling complementing lines (*YJ_lil-1+ ~9xMyc_1~LIL* and *YJ_lil-1+ ~9xMyc_2~LIL*), were determined using the MethylC-seq method ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}). In general, the complementing lines more closely resemble the *YJ lil-1_r7* mutant line than the *YJ_r7* control ([Figure 6C](#fig6){ref-type="fig"}), suggesting minimal complementation overall. Although the possibility of partial complementation at some loci cannot be excluded, even at the most robust set of DMRs, only 1 of 33 DMRs returned to control levels of DNA methylation ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}, hyper-CHH site 1. Of the remaining sites, eight showed consistent but modest decreases in DNA methylation (indicated by a single asterisks in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). However, 5 of these directly overlapped with known hyper-variable regions ([@bib59]). These findings demonstrate that re-introduction of LIL is not able to efficiently correct the observed hyper-methylation defects, which further supports the notion that these changes represent variation in methylation rather than a direct effect of the *lil* mutation.

Transcriptome profiling of *mbd7* and *lil* mutants {#s2-9}
---------------------------------------------------

To further investigate the role of the MBD7 complex in gene regulation, we assessed the effects of the *lil* and *mbd7* mutants on gene expression by transcriptome profiling. Similar to the approach taken for the DNA methylation profiling, two alleles of *LIL* (*lil-1* and *lil-2* in the *YJ* and *LUCH* backgrounds, respectively) and two alleles of *MBD7* (*mbd7-3* and *mbd7-4*) were compared to their corresponding controls ([Supplementary file 3](#SD5-data){ref-type="supplementary-material"}). Among these mutants, no overlapping mis-regulated genes were identified between the *lil* and *mbd7* alleles ([Supplementary file 3](#SD5-data){ref-type="supplementary-material"}) and only one of the genes previously identified as a target of MBD7 complex (*i.e.* down-regulated genes associated with hyper DMRs in the Columbia ecotype ([@bib28]; [@bib34]; [@bib52]; [@bib10]; [@bib53])) was consistently down-regulated in any of the mutants tested ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}). As some common alleles of *mbd7* were used in these studies and similar developmental stages were utilized, the factors leading to the differing results remain unclear. However, perhaps differences in growth conditions and/or the differing sensitivities and normalization procedures of the assays used to assess gene expression levels (*i.e.* mRNA-seq vs qPCR), as well as the already low expression levels of the down-regulated genes under our conditions, represent contributing factors ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}).

Given the absence of detectable endogenous targets transcriptionally regulated by the MBD7 complex, it is likely that this complex functions redundantly with other MBD-ACD complexes and/or is required only under specific conditions. Nonetheless, our findings demonstrate that this complex has the ability to regulate gene expression in a manner largely downstream of DNA methylation at *LUC* reporters. Firstly, we found that loss of the MBD7-LIL complex results in the silencing of these reporter constructs with minimal changes in DNA methylation. Secondly, we demonstrated that hyper-methylation at the 3' end of the *d35S* promoter in the *YJ* reporter does not appear to be sufficient to cause gene silencing ([Figure 5](#fig5){ref-type="fig"}). As such, the MBD7 complex joins a small number of factors including MOM1, MORC1, MORC6, ATXR5, and ATXR6, that can act primarily downstream of DNA methylation. However, unlike these other downstream effectors, which function to reinforce gene silencing, MBD7 and LIL represent the first anti-silencing complex placed downstream of DNA methylation, functioning to enable gene expression despite high levels of promoter DNA methylation.

Discussion {#s3}
==========

In this study, we identified two MBD-containing protein complexes and demonstrated a role for the MBD7 complex in promoting the expression of methylated transgenes. Furthermore, we found that while mutations in components of the MBD7 complex led to increased DNA methylation at the *d35S* promoter driving *LUC* expression, this methylation alone did not appear to be sufficient to cause *LUC* silencing. These findings, along with genome-wide analyses showing that only a small number of loci displayed a consistent hyper-methylation phenotype in *mbd7* and *lil* mutants, support an alternative hypothesis regarding the role of the MBD7 complex. Rather than functioning as part of the DNA demethylation pathway, as has been previously hypothesized ([@bib28]; [@bib34]; [@bib66]), our results suggest that the MBD7 complex may function in a manner largely downstream of DNA methylation. As very few proteins have been characterized that function downstream of DNA methylation, further characterization of this complex offers the potential to gain much needed insight into the mechanisms by which DNA methylation affects gene expression. Below, we summarize the current knowledge regarding the function and composition of MBD complexes from this and several previous studies ([@bib28]; [@bib34]; [@bib66]; [@bib78]; [@bib52], [@bib53]; [@bib37]). In addition, we highlight what is known about other factors that influence gene regulation downstream of DNA methylation.

The MBD7 complex and the DNA demethylation machinery {#s3-1}
----------------------------------------------------

The first anti-silencing factors discovered in *Arabidopsis* were a family of DNA glycosylases that recognize and remove methylated cytosine bases, leading to the release of gene silencing in a locus-specific manner ([@bib80]). Recently, additional anti-silencing factors have been identified through genetic screens and biochemical approaches revealing unanticipated connections between proteins that bind methylated DNA (MBD7 \[[@bib28]; [@bib34]; [@bib66]\] and ROS4/IDM1 \[[@bib53]; [@bib37]\]) and proteins with alpha crystallin domains (ACDs) (LIL/IDL1/IDM3 \[[@bib28]; [@bib34]\] and ROS5/IDM2 \[[@bib66]; [@bib78]; [@bib52]\]) in regulating the expression of methylated genes. As part of these screening efforts, the methylation status of one endogenous locus (*At1g26400*) and four reporter transgenes have been characterized. In all these cases, similar changes in DNA methylation and gene expression were observed in mutants of the demethylation machinery (either *ros1* single, or *rdd* triple mutants) or the MBD7 complex (*mbd7*, *lil*, *ros4*, and *ros5* mutants). Given this consistent genetic connection, previous studies have concluded that the various MBD and ACD proteins function in a common demethylation pathway with ROS1 to prevent hyper-methylation and enable gene expression, despite the fact that only modest increases in DNA methylation were observed ([@bib28]; [@bib34]; [@bib66]; [@bib78]; [@bib52], [@bib53]; [@bib37]). Here we show that the observed hyper-methylation and gene expression defects can be genetically uncoupled at the *YJ* reporter since *LUC* expression levels remain high in *ago4* and *nrpe1* mutants despite hyper-methylation patterns that are identical to those observed in *mbd7*, *lil*, or *rdd* mutant backgrounds. Furthermore, we show that on a genome-wide scale, the genetic connections between MBD7, LIL, and the demethylase machinery are no longer observed. Not only are there very few loci that show a consistent hyper-methylation phenotype across the various *mbd7* and *lil* datasets, but these loci represent a tiny fraction of the hyper-methylated loci in *rdd* mutants. Thus, while we cannot fully rule out a role for the MBD7 complex as a highly locus-specific regulator of the DNA demethylation pathway, nor do we know the extent to which other MBD-ACD complexes might function redundantly with the MBD7 complex and mask its role at endogenous targets and/or connections with the demethylase machinery, we currently favor a model based on our extensive transgene analysis in which the MBD7 complex functions largely downstream of DNA methylation to promote gene expression through a yet unknown mechanism.

Further support for the notion that the primary function of the MBD7 complex is downstream of DNA methylation comes from a comparison of the reporter transgenes used to identify components of this complex. While all these reporters contained *35S* promoters driving the expression of genes that are repressed in mutants of the MBD7 complex, no commonalities in the hyper-methylated regions were identified. For the *YJ* and *LUCH* reporters, hyper-methylation is restricted to the 3' end of the *d35S* promoter driving *LUC* expression ([Figures 4C](#fig4){ref-type="fig"} and [5A](#fig5){ref-type="fig"}). Interestingly, this hyper-methylation corresponds to two TGACG motifs previously shown be bound by a tobacco protein in a methylation sensitive manner ([@bib25]). However, this same region does not appear to be hyper-methylated in the *d35S* promoters present in the *SUC2* or *NPTII* reporters. At the *SUC* reporter the hyper-methylation is instead observed at the 5' end of the *35S* promoter ([@bib28]) and the hyper-methylation at the *NPTII* reporter is downstream of the *NPTII* gene, in the *NOS* terminator region ([@bib66]). Thus, as there is no clear consensus region that is hyper-methylated amongst these reporters, we posit that the hyper-methylation patterns may represent indirect effects caused by disruption of the MBD7 complex rather than locus specific regulation of DNA methylation.

Composition of MBD and ACD/HSP20-like complexes {#s3-2}
-----------------------------------------------

In the present study, MBD5 and MBD7 were found to associate with distinct sets of alpha crystallin domain (ACD)-containing proteins. Furthermore, MBD7 and its associated proteins, but not MBD5, were found to suppress the silencing of methylated luciferase (*LUC*) reporter transgenes, suggesting different roles for the MBD5 and MBD7 complexes. In addition to these purifications, each component of the MBD7 complex (MBD7, ROS4/IDM1, LIL/IDL1/IDM3, and ROS5/IDM2) has now been individually affinity purified and the co-purifying factors and their approximate relative abundances have been determined using Mass Spectrometry ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and refs \[[@bib28]; [@bib34]\]). With the exception of our 3xHA tagged MBD7 purification, all these Mass Spectrometry experiments yielded peptides corresponding to all four factors. However, in [@bib28] the purification of MBD7 yielded the most peptides matching LIL/IDM3, with relatively fewer hits to IDM1 and ROS5/IDM2, suggesting there may be a stable sub-complex of MBD7 and LIL/IDM3 in addition to the larger MBD7 complex. Taken together, these data demonstrate the existence of multiple MBD complexes, expanding the number of known MBD-ACD complexes, and revealing a functional difference between MBD5 and MBD7 complexes.

As a complement to the affinity purifications, many of the pair-wise interactions between the various MBD and ACD proteins have been determined using Y2H assays ([@bib28]; [@bib34]; [@bib66]; [@bib78]; [@bib52]). In several cases, subdomains important for these interactions have been mapped, revealing additional insights into the organization of these protein complexes. For example, the two ACD domain-containing proteins (LIL/IDL1/IDM3, and ROS5/IDM2) interact directly with each other ([@bib34]), with MBD7 ([@bib28]; [@bib34]; [@bib66]) and with ROS4/IDM1([@bib34]; [@bib78]; [@bib52]), whereas MBD7 and ROS4/IDM1 fail to show a direct interaction ([@bib28]; [@bib34]). This suggests the ACD-domain proteins may function to bridge the association between MBD7 and ROS4/IDM1. Furthermore, the interaction domains between ROS4/IDM1 and either LIL/IDL1/IDM3 or ROS5/IDM2 map to different regions of the ROS4/IDM1 protein ([@bib34]; [@bib78]) suggesting that both these ACD domain proteins could interact with ROS4/IDM1 at the same time. Similarly, Lang et al. and this study show that two adjacent regions in MBD7 are each sufficient to interact with LIL/IDL1/IDM3 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Thus, one can envision scenarios in which the two ACDs could compete for binding to the interaction domains in ROS4/IDM1 or MBD7, or cooperatively bind given their affinities for each other. Beyond these pair-wise interactions, [@bib78] demonstrated that ROS5/IDM2 forms higher-order structures that migrate at \~670 kDa after gel filtration, consistent with a 16-mer complex. This finding demonstrates that at least ROS5/IDM2, and possibly other ACD proteins, have the ability to oligomerize in a manner similar to canonical HSP20 proteins ([@bib57]). Although it remains unclear which interactions and structural features are required for the function of the MBD7 complex, the fact that loss of any component abolishes activity suggests a close tie between structure and function.

Regulation of gene expression downstream of DNA methylation {#s3-3}
-----------------------------------------------------------

While our understanding of the mechanisms through which gene expression is regulated downstream of DNA methylation remains quite limited, several factors have been shown to release gene silencing while having minimal effects on DNA methylation. Many of these factors, including MORC1, MORC6, ATXR5 and ATXR6, influence chromatin organization on a gross scale, such that loss of these factors results in de-compaction of peri-centromeric heterochromatin (i.e., chromocenters) ([@bib43]; [@bib21]) and the selective up-regulation of genes and transposons located within these regions ([@bib43]; [@bib21]). On the other hand, MOM1 appears to act on a finer scale to influence gene expression without significantly perturbing chromatin compaction ([@bib42]; [@bib51]). In *mbd7* and *lil* mutants, no obvious defects in chromocenter formation were observed, suggesting the MBD7 complex may act at a local level to enable the expression of methylated genes, perhaps antagonizing the function of MOM1, which has been shown to regulate expression at the *LUCH* reporter ([@bib68]). Alternatively, since there are several other MBD proteins known to bind methylated DNA (e.g., MBD5 and MBD6 ([@bib71]; [@bib56]; [@bib20]; [@bib74])) and several other ACD proteins closely related to LIL/IDL1/IDM3 and ROS5/IDM2 ([@bib57]) ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), these factors may act redundantly to regulate chromatin structure on a more global level.

Moving forward, it will be important to continue exploring the composition, dynamics, and regulatory roles of the various MBD and ACD complexes, and to begin investigating the genetic relationships between these complexes. Such experiments have the potential to uncover genomic targets regulated by these complexes in a redundant manner, and perhaps identify specific roles for these complexes during development. Finally, it will also be important to assess the relative contributions of the enzymatic and structural features associated with these complexes in modulating the local chromatin environment. This will provide further mechanistic insights into how different MBD and ACD complexes function together to regulate the expression of methylated regions of the genome.

Materials and methods {#s4}
=====================

Plant materials and transgenic lines {#s4-1}
------------------------------------

*Arabidopsis thaliana* Columbia-0 (Col) and Landsberg *erecta *(L*er*) ecotype plants were used in the present study. The *LUC*-based reporters *LUCH* ([@bib68]) and *YJ* ([@bib35]) are in the *rdr6-11* mutant background ([@bib48]) in all lines used for this study and were originally generated in the Col background. The *lil-1*, *ros4-2* and *ros4-3* mutants were recovered from an EMS screen in the *YJ* background while the *lil-2* mutant was recovered from a T-DNA screen in the *LUCH* background. The following additional mutants were introduced into the *YJ* background (Col ecotype) by crossing: *mbd7-3* (GABI_067_A09) ([@bib27]) (formerly named *mbd7-1* in ([@bib34]) and renamed to avoid duplicate allele names with other publications ([@bib28])), *mbd7-4* (SALKseq_080774) (unpublished), *mbd5-3* (SAILseq_750_A09) (unpublished), *ros5-4* (SALK_138229 also kown as *idm2-2* ([@bib52]; [@bib1]), *ago4-6* ([@bib1]), *nrpe1-11* ([@bib49]), and *ros1-3 dml2-1 dml3-1* ([@bib47]). Finally, *mbd5-1* (CSHL_ET8226) ([@bib63]) and *mbd7-5* (GT_5\_107435) ([@bib63]), which are in the L*er* ecotype, were crossed into the *YJ* reporter that was introgressed into the L*er* ecotype through 5 backcrosses.

To generate the *MBD5-3xFlag*, *MBD7-3xHA*, and *MBD7-3xFlag* transgenes, the genomic regions of *MBD5* and *MBD7*, including their endogenous promoter regions, were amplified by PCR using the primer pairs JP3845/JP3891 and JP5523/JP5525, respectively ([Supplementary file 4](#SD6-data){ref-type="supplementary-material"}). The PCR products were cloned into the pENTR/D/TOPO vector per manufacturer's instructions (Invitrogen). A carboxy terminal 3xFlag or 3xHA tag (described in \[[@bib32]\]) was added at an AscI site present in the pENTR/D/TOPO backbone downstream of the *MBD5* or *MBD7* inserts. The resulting plasmids were recombined into a modified version of the pEG302 plasmid as described in [@bib23] using a Gateway LR clonase kit (Invitrogen) and transformed into Col or *YJ mbd7-5* plants using the floral dip method.

To generate the *pLIL:9xMyc-LIL* transgene, the genomic region of *LIL* encompassing the promoter and coding sequence up to the stop codon was amplified by PCR using primers HSP20-proF1 and HSP20-R3 from Col genomic DNA. The genomic fragment was cloned into pENTR/D-TOPO (Invitrogen, K2400-20) to result in pENTR/D-TOPO-LIL. Site-directed mutagenesis was performed using the Stratagene kit XL II with this clone using primers HSP20-mut3 and HSP20-mut4 to introduce a *Kpn*I site near the start codon of LIL. A 9xMyc-BLRP fragment was released from the pCR2.1::KpnI 9×Myc-BLRP plasmid ([@bib30]) by *Kpn*I digestion and cloned into the *Kpn*I site of the pENTR/D-TOPO-LIL plasmid to result in an N-terminal fusion of *9xMyc* to *LIL*. The insert in the entry vector was then recombined into pGWB204 ([@bib44]) using a Gateway LR Clonase kit (Invitrogen, 11791--019) and transformed into *YJ lil-1* plants using the floral dip method.

*LUCH* and *YJ* genetic screens {#s4-2}
-------------------------------

Mutant populations in the *YJ* and *LUCH* backgrounds were generated via ethyl methanesulfonate (EMS) or T-DNA mutagenesis, respectively. For EMS mutagenesis, 1 ml of seeds (around 10,000 seeds) were washed with 0.1% Tween 20 for 15 min, treated with 0.2% EMS for 12 hr and washed three times with 10 ml water for 1 hr with gentle agitation. For T-DNA mutagenesis, pEarleygate303 was modified to remove the Gateway cassette then transformed into the *LUCH* line. Mutants with lower LUC activity, based on LUC live imaging, were isolated in the M2 generation of the EMS population and the T2 generation of the T-DNA population. The isolated mutants were backcrossed to the respective parental lines two times before further analysis.

Mapping of the *ros4-2* and *ros4-3* mutations {#s4-3}
----------------------------------------------

The *YJ ros4-2* and *YJ ros4-3* mutants were isolated from the *YJ* EMS screen and crossed to the corresponding *YJ* lines in the L*er* background to generate the F2 mapping populations. For *YJ ros4-2*, 28 F2 plants with reduced LUC activity were used for rough mapping, and the mutation was linked to the center of the upper arm of chromosome 3. SSLP and dCAPS markers were designed using identified polymorphisms between the Col and L*er* accessions (<http://arabidopsis.org/browse/Cereon/index.jsp>). Fine mapping narrowed the region to a 280 kb window spanning the K15M2, F4B12, K7L4, MJK13, MQD17 and MSJ11 BAC clones. Candidate gene sequencing uncovered a G-to-A mutation that introduced a premature stop codon in the seventh exon of *At3g14980*, and the mutation was subsequently referred to as *ros4-2*. For *YJ ros4-3*, 27 F2 plants with reduced LUC activity were used for rough mapping, and linkage to the same mapping region of *ros4-2* was observed. Sequencing of *At3g14980* revealed a G-to-A mutation that introduced a premature stop codon in the second exon.

Mapping of the *lil-1* and *lil-2* mutations {#s4-4}
--------------------------------------------

The *YJ lil-1* and *LUCH lil-2* mutants were isolated from the *YJ* EMS screen and the *LUCH* T-DNA screen, respectively, and crossed to the corresponding *LUC* lines in the L*er* background to generate the F2 mapping populations. For *YJ lil-1*, 32 F2 plants with reduced LUC activity were used for rough mapping, and the mutation was linked to the center of the upper arm of chromosome 1. SSLP and dCAPS markers were designed using identified polymorphisms between the Col and L*er* accessions (<http://arabidopsis.org/browse/Cereon/index.jsp>). Fine mapping narrowed the region to a 160 kb window spanning the F5M15, F2D10 and F9H16 BAC clones. Candidate gene sequencing uncovered a G-to-A mutation in the splice acceptor site of *At1g20870*, and the mutation was subsequently referred to as *lil-1*. For *LUCH lil-2*, 27 F2 plants with reduced LUC activity were used for rough mapping, and linkage to the same mapping region of *lil-1* was observed. Sequencing of *At1g20870* revealed a C-to-T mutation that introduced a premature stop codon in the first exon.

Yeast two-hybrid screen {#s4-5}
-----------------------

The full-length coding sequence of *LIL* was amplified with primers HSP20T7fl F and HSP20T7fl R and cloned into the bait vector pGBKT7 at the *Nde*I and *Bam*HI sites to be fused in-frame with the sequence encoding the GAL4 DNA-binding domain (BD). The *Arabidopsis* cDNA library cloned into the prey vector pGADT7-RecAB was constructed by Clontech. All experiments using the yeast two-hybrid system were carried out according to the manufacturer's instructions (Clontech, Matchmaker GAL4 Two-Hybrid System 3 and Libraries User Manual, PT3247-1). The bait plasmid pGBKT7-LIL and the prey library DNA were co-transformed into the yeast strain AH109. The resulting progeny were first selected on SD/-Leu/-Trp/-His/-Ade plates then tested for β-galactosidase activity to eliminate false positives. Plasmids harboring positive prey cDNAs were isolated and sequenced to ensure that the cDNAs had been fused in-frame with the sequence encoding the GAL4 AD domain.

To identify the interaction domains, the alpha crystallin/Hsp20 domain of *LIL* was amplified with primers HSP20T7D1F and HSP20T7D1R and cloned into pGBKT7 as the bait LILD1. The *LIL* sequence 5' to the alpha crystallin/Hsp20 domain was amplified with primers HSP20T7N3F and HSP20T7N3R and cloned into pGBKT7 as the bait LILN3. Full-length or truncated *MBD5*, *MBD6* and *MBD7* cDNAs were cloned into pGADT7. Full-length *MBD5* coding sequence was amplified with primers MBD5ADfl F and MBD5ADfl R; Full-length *MBD6* coding sequence was amplified with primers MBD6ADfl F and MBD6ADfl R; Full-length *MBD7* coding sequence was amplified with MBD7ADfl F and MBD7ADfl R. The methyl-CpG-binding domain of *MBD5* was amplified with primers EcoRI-MBD5d and MBD5d-BamHI and cloned into pGADT7 as prey MBD5d. Similarly, the methyl-CpG-binding domain of *MBD6* was amplified with MBD6d-BamHI and EcoRI-MBD6d and cloned into pGADT7 as prey MBD6d. For MBD7, the second methyl-CpG-binding domain, including partial sequence of the third methyl-CpG-binding domain, was amplified with EcoRI-MBD7d2 and MBD7d2-BamHI and cloned into pGADT7 as prey MBD7d2. The third methyl-CpG-binding domain of MBD7 was amplified with EcoRI-MBD7d3 and MBD7d3-BamHI and cloned into pGADT7 as prey MBD7d3. Sequences of primers used in the plasmid construction can be found in [Supplementary file 4](#SD6-data){ref-type="supplementary-material"}. Colonies containing both bait and prey plasmids were selected by growing yeast on selective dropout medium lacking Trp and Leu (SD/-Trp/-Leu) at 30°C. They were subsequently plated on selective dropout medium lacking Trp, Leu, Ade and His (SD/-Trp/-Leu/-Ade/-His) and grown at 30°C to test interactions between bait and prey.

Affinity purification and Mass Spectrometry {#s4-6}
-------------------------------------------

Affinity purification and Mass Spectrometry of MBD5 and MBD7 were performed largely as described in [@bib30]. Briefly, for each replicate of MBD5, approximately 14 g of flower tissue from MBD5-3xFlag transgenic T~4~ plants, or from wild type Col plants, were ground in liquid nitrogen. For replicates one and two, the tissue was re-suspended in 75 mL of lysis buffer 1 (LB1: 50 mM Tris pH7.6, 150 mM NaCl, 5 mM MgCl~2~, 10% glycerol, 0.1% NP-40, 0.5 mM DTT, 1 µg/µL pepstatin, 1 mM PMSF and one protease inhibitor cocktail tablet (Roche, 14696200)), while replicate three was re-suspended in 75 mL of low salt lysis buffer 2 (LB2: LB1 replacing 150 mM NaCl with 100 mM NaCl). In all three cases, immunoprecipitation utilized 250 μL of 50% M2 FLAG-agarose slurry (Sigma, A2220) and proteins were eluted from the beads by competition with 3xFLAG peptide (Sigma, F4799).

For replicates one and two of MBD7, approximately 10 or 15 g of flower tissue from MBD7-3xHA transgenic T~4~ plants or from wild type Col plants, respectively, were ground in liquid nitrogen and re-suspended in either 50 mL of LB1 (replicate 1) or 75 mL of a triton lysis buffer 3 (LB3: LB1 replacing 0.1% NP-40 with 1% Triton X-100) (replicate 2). Immunoprecipitation utilized 250 μL of 50% HA-conjugated slurry (Roche, 11815016001) and proteins were eluted from the beads by competition with HA peptide (Thermo, 26184). For the third replicate of MBD7, approximately 10 g of flower tissue from MBD7-3xFLAG transgenic plants or from wild type Col plants were ground in liquid nitrogen and re-suspended in 50 mL of lysis buffer 1 (LB1). Immunoprecipitation utilized 250 μL of 50% Anti-FLAG M2 Magnetic bead slurry (Sigma, M8823) and proteins were eluted from the beads by competition with 3xFlag peptide (Sigma, F4799). Eluted proteins were TCA precipitated and subjected to Mass Spectrometry as described in [@bib30].

Luciferase imaging {#s4-7}
------------------

For [Figure 1](#fig1){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, seeds were surface-sterilized and planted on half-strength Murashige and Skoog (MS) media supplemented with 0.8% agar and 1% sucrose then stratified at 4°C for three days. Plants were grown in a growth incubator at 23°C under continuous light. 10-day-old seedlings were used for all of the experiments. Luciferase live imaging was performed as previously described ([@bib68]).

For [Figure 2](#fig2){ref-type="fig"} (*YJ* lines), [Figure 5](#fig5){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}, seeds were surface-sterilized and planted on Linsmaier and Skoog (LS) media (Caissen, LSP03) supplemented with 0.8% agar, then stratified at 4°C for three days. Plants were grown in a growth incubator at 23°C under short day conditions (8 hr light, 16 hr dark). 10-day-old seedlings were used for all of the experiments. Luciferase live imaging was performed using a CCD camera (Andor, iKon-M 934) and PlantLab software (BioImaging Solutions).

5-aza-2'-deoxycytidine treatment and Luciferase imaging {#s4-8}
-------------------------------------------------------

For 5-Aza-dC (Sigma, A3656) treatment, plants were grown on Murashige and Skoog (MS) media containing 0.8% agar, 1% sucrose and 7 μg/ml 5-Aza-dC for 2 weeks. Luciferase live imaging was performed as previously described ([@bib68]).

RNA extraction and RT-PCR {#s4-9}
-------------------------

For [Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} (*LUCH* lines), [Figure 3](#fig3){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, RNA was extracted from a pool of 10-day-old seedlings using TRI reagent (Molecular Research Center, TR118) and treated with DNaseI (Roche, 04716728001). cDNA was synthesized using RevertAid Reverse Transcriptase (Thermo Scientific, EP0441) and oligo-dT primer (Thermo Scientific, SO131). RT-qPCR was performed on a Bio-Rad C1000 thermal cycler equipped with a CFX detection module using iQ SYBR Green Supermix (Bio-Rad, 170--0082). For [Figure 2](#fig2){ref-type="fig"} (*YJ* lines), [Figure 5](#fig5){ref-type="fig"}, [Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}, RNA was extracted from a pool of 10-day-old seedlings using Zymo Research Quick-RNA Miniprep Kit (Zymo, R1054S). cDNA was synthesized using Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814). RT-qPCR was performed on a Bio-Rad CFX384 Real-Time System using iTaq Universal SYBR Green Supermix (Bio-Rad, 172--5124). Quantification of transgene expression was performed in biological triplicate, unless otherwise indicated. All experiments were conducted per the manufacturers' instructions. The primers used in the study are listed in [Supplementary file 4](#SD6-data){ref-type="supplementary-material"}.

McrBC-PCR {#s4-10}
---------

Genomic DNA was extracted from a pool of 10-day-old seedlings using the CTAB method ([@bib55]). Three units of McrBC (New England Biolabs, M0272) were used to treat 200--500 ng of DNA at 37°C for 25 min to overnight. A mock experiment was performed in parallel using DNA that had not been treated with McrBC. Either regular PCR or quantitative PCR using iTaq Universal SYBR Green Supermix (Bio-Rad, 172--5124) was performed to determine the level of methylation. For both regular PCR and qPCR, *ACTIN1*, which lacks cytosine methylation, was used as the internal loading control. The relative methylation was calculated as 100--100 × 2^Ct(mock)\ -\ Ct(treated)^, such that higher relative levels of PCR amplification correspond to higher levels of methylation. The primers used in the study are listed in [Supplementary file 4](#SD6-data){ref-type="supplementary-material"}.

Western blotting {#s4-11}
----------------

Western blot analysis of MBD7-3xHA transgenic lines was performed using 0.1 g of flower tissue. Tissue was mechanically disrupted and homogenized in cold IP buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5 mM MgCl~2~, 10% Glycerol, 0.1% NP40) with protease inhibitors. The lysate was resolved on a 10% Bis-Tris Criterion XT Gel (Bio-Rad, 345--0112) then transferred to a PVDF membrane (GE Healthcare Bio-Sciences, 10600023) and probed with anti-HA-Peroxidase (Roche, 12013819001) (1:2000). MBD7-3xHA was detected by autoradiography using ECL2 Western Blotting Substrate (Pierce, 80196).

Western blot analysis of 9xMyc-LIL transgenic lines was performed using 0.3 g of 10-day-old seedlings. Tissue was mechanically disrupted and homogenized in cold IP buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 5 mM MgCl~2~, 10% Glycerol, 0.1% NP40) with protease inhibitors. 9xMyc-LIL was immunoprecipitated using Dynabeads Protein G (Invitrogen, 10004D) incubated with monoclonal anti-Myc Tag antibody (Millipore, 05--724). The immunoprecipitate was resolved on a 10% TGX Mini-Protean Gel (Bio-Rad, 456--8035), transferred to a PVDF membrane (GE Healthcare Bio-Sciences, 10600023) and probed with a monoclonal anti-Myc primary antibody (Millipore, 05--724) (1:4000) and a HRP-conjugated Goat anti-mouse secondary antibody (BioRad, 170--6516) (1:5000). 9xMyc-LIL was detected by autoradiography using ECL2 Western Blotting Substrate (Pierce, 80196).

Traditional bisulfite sequencing {#s4-12}
--------------------------------

Approximately 2 μg of genomic DNA, extracted using the CTAB method from 10-day-old seedlings, was bisulfite-treated using the MethylCode Bisulfite Conversion Kit (Invitrogen, MEV50). Amplification of specific genomic loci was performed using transgene-specific primers ([Supplementary file 4](#SD6-data){ref-type="supplementary-material"}; d35S2 tBS Forward and d35S2 tBS Reverse), KAPA HiFi HotStart Uracil+ ReadyMix PCR Kit (KAPA Biosystems, KK2801) and the following PCR conditions: 95°C for 5 min; 98°C for 30 s; 2 cycles of 98°C for 30 s, 66.5°C for 1 min and 72°C for 1 min; 2 cycles of 98°C for 30 s, 65.5°C for 1 min and 72°C for 1 min; 2 cycles of 98°C for 30 s, 64.5°C for 1 min and 72°C for 1 min; 2 cycles of 98°C for 30 s, 63.5°C for 1 min; 32 cycles of 98°C for 30 s, 62.5°C for 1 min and 72°C for 1 min; and 72°C for 15 min. PCR products were run on a 2% agarose gel and \~500 bp bands were purified using the QIAGEN Gel Extraction Kit (Qiagen, 28704). Purified PCR products were cloned into the pCRII-TOPO vector using the Invitrogen ZeroBlunt TOPO PCR cloning kit (Invitrogen, 450245). The resulting plasmids were transformed into One-Shot TOP10 Chemically Competent *E. coli* cells (Invitrogen, C404003). Sequencing was performed from bacterial glycerol stocks of 24 different colonies using the M13 Forward (−21) primer. A small number of clonal sequences as well as sequences with regions of potential non-conversion were removed from the analysis. Sequences were aligned to a reference using the CLC Main Workbench ([www.clcbio.com](http://www.clcbio.com)) and visualized using cymate. The percent methylation (number of methylated cytosines divided by the total number of cytosines) was calculated for each cytosine. The average percent methylation was reported for specific ranges within the *35S* sequence.

Small RNA library construction, sequencing, and bioinformatics analysis {#s4-13}
-----------------------------------------------------------------------

Total RNA was size-fractionated by electrophoresis and RNAs 15 to 40 nt in length were purified and subjected to library construction. Small RNA libraries were prepared using the TruSeq Small RNA Sample Preparation Kit (Illumina, RS-200--0012) according to the manufacturer's instructions and sequenced with Illumina\'s HiSeq2000 platform at the UCR Institute for Integrative Genome Biology (IIGB) genomic core facility. 3' adapter sequences were trimmed from the raw reads using custom Perl scripts ([Source code 1](#SD2-data){ref-type="supplementary-material"}). Reads \<18 nt after adapter trimming or corresponding to rRNA, tRNA, snRNAs and snoRNAs were discarded. The remaining reads were aligned to the TAIR10 Arabidopsis genome or the *YJ*/*LUCH* transgene sequence using bowtie allowing for perfect match only and multiple mapping (-v 0 --m 1000) or unique mapping (-v 0 --m 1).

MethylC-seq library construction and sequencing {#s4-14}
-----------------------------------------------

MethylC-seq libraries corresponding to the '\_r2, \_r5, and_B' series ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}) were prepared as follows: Genomic DNA was extracted using the DNeasy Plant Mini Kit (Qiagen, 69104). One microgram of genomic DNA was sonicated into fragments 150 to 300 bp in length using a Diagenode Bioruptor, followed by purification with the PureLink PCR Purification Kit (Invitrogen, K3100-01). DNA ends were repaired using the End-It DNA End-Repair Kit (Epicentre, ER0720), and the DNA fragments were purified using the Agencourt AMPure XP-PCR Purification system (Beckman Coulter, A63880). The purified DNAs were adenylated at the 3' end using the polymerase activity of Klenow Fragment (3'→5' exo-) (New England Biolabs, M0212), followed by purification using the Agencourt AMPure XP-PCR Purification system. The methylated adapters in the TruSeq DNA Sample Preparation Kit (Illumina, FC-121--2001) were ligated to the DNA fragments using T4 DNA Ligase (New England Biolabs, M0202). After purification using AMPure XP beads, less than 400 ng DNA was subjected to bisulfite conversion using the MethylCode Bisulfite Conversion Kit (Invitrogen, MECOV-50). PfuTurbo Cx Hotstart DNA polymerase (Agilent, 600414) and the following PCR conditions were used for amplification: 95°C for 2 min; 9 cycles of 98°C for 15 s, 60°C for 30 s and 72°C for 4 min; and 72°C for 10 min.

All the remaining MethylC-seq libraries ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}) were prepared following a slightly modified protocol as detailed in [@bib65]. Genomic DNA was extracted from 10-day-old seedlings using the DNeasy Plant Mini Kit (Qiagen, 69104). 2 μg of genomic DNA was sonicated into 200 bp fragments using a Covaris S2 Sonicator, followed by purification with Sera-Mag Magnetic SpeedBeads (ThermoScientific, 65152105050250). DNA ends were repaired using the End-It DNA End-Repair Kit (Epicentre, ER81050), and the DNA fragments were purified using Sera-Mag Magnetic SpeedBeads. The purified DNAs were adenylated at the 3' end using the polymerase activity of Klenow Fragment (3'→5' exo-) (New England Biolabs, M0212), followed by purification using Sera-Mag Magnetic SpeedBeads. The methylated adapters in the NEXTflex Bisulfite-Seq Barcodes Kit (BIOO Scientific, 511911) were ligated to the DNA fragments using T4 DNA Ligase (New England Biolabs, M0202). After purification using Sera-Mag Magnetic SpeedBeads, the DNA was subjected to bisulfite conversion using the MethylCode Bisulfite Conversion Kit (Invitrogen, MECOV-50). KAPA HiFi HotStart Uracil+ ReadyMix PCR Kit (KAPA Biosystems, KK2801) and the following PCR conditions were used for amplification: 95°C for 2 min; 98°C for 30 s; 4 cycles of 98°C for 15 s, 60°C for 30 s and 72°C for 4 min; and 72°C for 10 min. After purification using Sera-Mag Magnetic SpeedBeads, the libraries were pooled and then sequenced and processed by the Next Generation Sequencing Core at the Salk Institute for Biological Studies.

Illumina sequencing {#s4-15}
-------------------

MethylC-seq libraries corresponding to the '*YJ*\_r2, *YJ_lil-1*\_r2 and Col_B' samples ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}) were sequenced solely using HiSeq 2000 with the 101-cycle single-end sequencing mode (Illumina). MethylC-seq libraries corresponding to the '\_r1, \_r1_r2, \_r6, and \_r7,' series were sequenced solely using the Illumina HiSeq 2500 v4 at the Salk NGS Core with the 50-cycle single-end sequencing mode (Illumina). MethylC-seq libraries corresponding to the 'Col_r5, *rdd*\_r5, *LUCH*\_r2, *LUCH_lil-2*\_r2, *YJ*\_r5, and *YJ_lil-1*\_r5' samples ([Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}) where sequenced using both sequencers (HiSeq 2000 and 2500) using the 101- and 50-cycle single-end modes, respectively, and the data was combined for the final analyses.

MethylC-seq analysis at the *YJ* and *LUCH* transgenes {#s4-16}
------------------------------------------------------

Illumina sequence reads were filtered to remove duplicate reads either with prinseq ([@bib58]), using the remove exact duplicates option (-derep 1), or the BSseeker2 ([@bib15]) filterReads.py script, using default conditions. The reads were then mapped to the *YJ* or *LUCH* transgene sequences ([Supplementary file 1D](#SD3-data){ref-type="supplementary-material"}; LUC_transgenes.genome) using bsmap-2.74 ([@bib70]) with the default parameters, allowing two mismatches (-v 2). Since the *d35S* promoters driving the expression of the *LUC* and *NPTII* genes are 94% identical, both unique and multi-mapping reads were included, with the maximum number of equal best hits set to 2 (-w 2). The percent methylation levels (mC reads/total C reads x 100) at each cytosine were quantified using the bsmap methratio.py script, reporting loci with zero methylation ratios (-z). The data was converted to a wiggle format for genome browser visualization with a coverage filter set to 5 ([Supplementary file 1D](#SD3-data){ref-type="supplementary-material"}; TransgeneWig). In addition, the methylation levels were also determined using only uniquely mapping reads using the BSseeker2 bs_seeker2-align.py script, using the bowtie1 aligner (version bowtie-1.0.0) ([@bib29]) and allowing for two mismatches (-m 2) ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Mapping and coverage statistics are presented in [Supplementary file 1A and 1B](#SD3-data){ref-type="supplementary-material"}, respectively.

Genome-wide MethylC-seq mapping and quantification of DNA methylation levels {#s4-17}
----------------------------------------------------------------------------

Illumina reads were filtered to remove duplicated and low quality reads using the BSseeker2 FilterRead.py script and then mapped to the TAIR10 genome using the BSseeker2 bs_seeker2-align.py script, using the bowtie1 aligner (version bowtie-1.0.0) ([@bib29]) and allowing for two mismatches (-m 2). Mapping and coverage statistics are presented in [Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}.

The percent methylation level at each cytosine was calculated using the BSseeker2 bs_seeker2-call_methylation.py script requiring a minimum coverage of 4 reads (-r 4). The resulting CGmap files were used to generate wiggle files containing the percent methylation levels of cytosines covered by at least four reads in the CG, CHG, and CHH contexts individually ([Supplementary file 1F](#SD3-data){ref-type="supplementary-material"}; Cov4_noFilter_Wig). The global % methylation in the CG, CHG, and CHH contexts is presented in [Supplementary file 1E](#SD3-data){ref-type="supplementary-material"}.

DMR calling and DMR lists {#s4-18}
-------------------------

DMRs were identified using parameters outlined in [@bib62]. Briefly, the genome was split into 100 bp, non-overlapping bins and the methylation level across each bin in the CG, CHG, or CHH context was calculated independently using the percent methylation values in the wiggle files (see **Genome-wide MethylC-seq mapping and quantification of DNA methylation levels**). The methylation values in each bin were then compared between two samples to call DMRs with the following requirements: (1) To account for 100 bp regions of the genome with low numbers of cytosines and for regions that display lower than average coverage, only bins with at least four cytosines in the given context that are covered by at least four reads in both samples being compared were included in the DMR analysis. (2) Only bins with an absolute change in methylation of 0.4, 0.2, and 0.1 for the CG, CHG, and CHH contexts, respectively, and with an adjusted p-value of ≤0.01 were identified as DMRs. The number of DMRs identified for each mutant dataset and their genomic locations are presented in [Supplementary file 2A](#SD4-data){ref-type="supplementary-material"} and [Supplementary file 1F](#SD3-data){ref-type="supplementary-material"}; DMRs, respectively.

To determine directly overlapping DMRs between datasets, the bedops interest (-i) ([@bib46]) function was utilized to identify common DMRs, and to maintain a common DMR size of 100 bp the bedops chop (-w 100) function was used. The number of DMRs that overlap between 2, 3, 4, 5 or all six datasets and their genomic locations are shown in [Supplementary file 2B-F](#SD4-data){ref-type="supplementary-material"} and [Supplementary file 2G-J](#SD4-data){ref-type="supplementary-material"}, respectively. To identify DMRs co-regulated by the MBD7-LIL complex in a more relaxed manner, we first generated six master lists of DMRs (hyper and hypo DMRs in the CG, CHG, or CHH contexts; [Supplementary file 2K-P](#SD4-data){ref-type="supplementary-material"} Master_DMR_lists; relevant to [Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) that included all the DMRs called amongst the 6 pairs of samples (3 replicates of *lil-1*, *lil-2*, *mbd7-3* and *mbd7-4* with their respective controls). The methylation levels at the DMRs were then determined (see **Heatmaps**) and clusters of DMRs showing either increased or decreased DNA methylation levels across all the *lil* and *mbd7* datasets were selected ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"} and [Supplementary file 2Q-U](#SD4-data){ref-type="supplementary-material"}; Relaxed_DMR_lists). To determine the overlap of these DMRs with previously annotated features including body methylated genes ([@bib64]), the bedops \--element-of and \--not-element-of functions were used with the overlap threshold set at 1 bp. Overlaps with body-methylated genes were also inspected manually to remove body-methylated genes with significant non-CG methylation and to annotate additional genic regions that contain methylation only in the CG context ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}).

To identify regions of the genome that contain hyper-methylated DMRs, irrespective of their sequence context ([Figure 6D](#fig6){ref-type="fig"}), a set of merged hyper mC DMRs were generated as follows. First all hyper DMRs of the same context that were within 300 bp were merged into a single region using the mergeBed function with the --d 300 option. Then these merged CG, CHG, and CHH DMRs were combined using the bedops --everything function and finally, directly adjacent regions were joined using the mergeBed function. Merged DMRs for the relaxed set of DMRs common between the *mbd7* and *lil* datasets as well as for the *rdd* datasets are available as part of [Supplementary file 2V and 2W](#SD4-data){ref-type="supplementary-material"} and were used for [Figure 6D](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"}.

Heatmaps {#s4-19}
--------

Heatmaps showing the levels of methylation across individual DMRs were generated using the HOMER (Hypergeometric Optimization of Motif EnRichment) suite of genomics tools ([@bib18]). Homer 'TagDirectory' files cataloging the DNA methylation levels in the CG, CHG, and CHH contexts for each MethylC-seq experiment were generated using the wiggle files generated during the MethylC-seq mapping process (see **Genome-wide MethylC-seq mapping and quantification of DNA methylation levels**) at a precision level of three decimals (-precision 3). The methylation level over each DMR was then calculated using the annotatePeaks.pl script with the following options (none -ratio -noadj -size given -nogene -len 1 --ghist). Heatmaps were generated using Cluster ([@bib8]) with the following options (-m a -g 4 -e 0) and were visualized in Java Treeview. The data is either represented in a clustered form ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) or an unclustered form ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). For the unclustered data, the DMRs were ordered based on the difference in the average values for the mutants and their controls (e.g. in [Figure 6C](#fig6){ref-type="fig"} the averaged difference was calculated using this equation \[(*YJ_lil-1*\_r1 + *YJ_lil-2*\_r2 + *YJ_lil-5*\_r5 + *YJ_mbd7-3*\_r1 + *YJ_mbd7-4*\_r1)/5\] -- \[(*YJ*\_r1 + *YJ*\_r2 + *YJ*\_r5)/3\] and the rows were sorted largest to smallest).

Library construction for mRNA-seq, data processing and identification of differentially expressed genes {#s4-20}
-------------------------------------------------------------------------------------------------------

For Col, *mbd7-3* and *mbd7-4*, RNA-seq libraries were generated using 2 μg of DNaseI-treated RNA and the NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs, E7530) according to the manufacturer's instructions. The libraries were pooled and then sequenced and processed by the Next Generation Sequencing Core at the Salk Institute for Biological Studies.

For *YJ, YJ lil-1*, *LUCH*, and *LUCH lil-2*, 10-day-old seedlings were used for RNA extraction using Trizol (Invitrogen, 15596--018), and the extracted RNA was treated with DNase I (Roche, 04716728001). 2 ug of the DNase I-treated RNA were used for RNA-seq library construction with the TruSeq RNA Sample Preparation Kit v2 (Illumina, FC-122--1002). The libraries were sequenced on an Illumina HiSeq 2000 instrument at the genomics core facility at UC Riverside. Image analysis and base calling were performed using the standard Illumina pipeline, version RTA 1.13.48.

For all samples, only reads that passed the Illumina quality control steps were included in subsequent analyses, and reads with multiple copies were considered as a single read for the mapping procedure. The reads were mapped to the TAIR10 *Arabidopsis* genome using TopHat v2.0.4 with default settings ([@bib26]). Reads that mapped to multiple regions were discarded. The number of reads mapped to each gene was counted using a Perl script. Differentially expressed genes were identified using the R package edgeR ([@bib54]) from BioConductor (<http://www.bioconductor.org>). The false discovery rate (FDR) \<= 0.05 and fold change \>= 2 were used as the cutoff. For [Figure 6---figure supplement 4](#fig6s4){ref-type="fig"} the FPKM values were determined using the Homer analyzeRepeats.pl script using the -fpkm option for normalization.

MBD7 ChIP {#s4-21}
---------

For the MBD7 ChIP-qPCR assays, tissue from F1 hybrids between the *YJ* and MBD7-GFP ([@bib66]) lines was used and the ChIP assays were preformed following previously described procedures ([@bib39]). Briefly, 5 g of 10-day-old seedlings were first ground in liquid nitrogen and then crosslinked in 1% formaldehyde (Amresco) for 10 min on ice. The chromatin was fragmented to 500 \~ 800 bp by sonication and the lysate was pre-cleared with 100 μl protein A agarose beads (Roche) for two hours before incubation with either no antibody or anti-GFP (Abcam, ab290) overnight at 4°C. Crosslinking was reversed by incubation at 65°C for 8 hr, afterwards, the DNA was purified with columns from the Qiagen plasmid extraction kit (Qiagen, 27106). Real-time PCR was conducted using input, no antibody control and antibody bound DNA in triplicates. Three biological repeats were performed to ensure reproducibility. All primers used in the ChIP-qPCR are listed in [Supplementary file 4](#SD6-data){ref-type="supplementary-material"}.

Accession numbers {#s4-22}
-----------------

Genomic sequences reported in this manuscript have been submitted to NCBI GEO (<http://www.ncbi.nlm.nih.gov/geo>): gene expression, small RNA and DNA methylation data are under accession numbers GSE83557, GSE59639, and GSE83355, respectively.
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10.7554/eLife.19893.021

###### Custom Perl script used to trim 3' adapter sequences 839 from raw reads.

**DOI:** [http://dx.doi.org/10.7554/eLife.19893.021](10.7554/eLife.19893.021)

10.7554/eLife.19893.022

###### MethylC-seq and smRNAseq data processing

\(A\) *LUC* reporter MethylC-seq mapping information. (B) *LUC* reporter MethylC-seq coverage. (C) *LUC* reporter mapping and coverage of small RNA data. (D) List of supplemental materials for *LUC* Reporter Genomics. (E) TAIR10 genome mapping and coverage information. (F) List of supplemental materials for the genome-wide analyses (TAIR10).

**DOI:** [http://dx.doi.org/10.7554/eLife.19893.022](10.7554/eLife.19893.022)

10.7554/eLife.19893.023

###### DMRs and DMR overlaps

\(A\) Hyper and Hypo DMRs in the CG, CHG and CHH contexts. (B-F) Direct DMR overlaps in the various *lil* and *mbd7* datasets corresponding to 2-way, 3-way, 4-way, 5-way, and 6-way overlaps, respectively. (G-J) six way DMR coordinates in the hyper CG, CHG, CHH and hypo CG contexts, respectively. (K-P) Master DMR coordinates in the hyper CG, CHG, CHH, and hypo CG, CHG, and CHH contexts, respectively. (Q-U) Relaxed DMR coordinates in the hyper CG, CHG, CHH, and hypo CG, CHG, and CHH contexts, respectively. (V) *mbd7* and *lil* hyper DMRs, all mC contexts merged. (W) *rdd* hyper DMRs, all mC contexts merged.

**DOI:** [http://dx.doi.org/10.7554/eLife.19893.023](10.7554/eLife.19893.023)

10.7554/eLife.19893.024

###### Analysis of *lil* and *mbd7* RNAseq experiments.

**DOI:** [http://dx.doi.org/10.7554/eLife.19893.024](10.7554/eLife.19893.024)

10.7554/eLife.19893.025

###### Primers.

**DOI:** [http://dx.doi.org/10.7554/eLife.19893.025](10.7554/eLife.19893.025)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The MBD7 complex promotes expression at methylated transgenes without significantly altering their methylation status\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Jessica Tyler as the Senior Editor and Steven Henikoff as Guest Reviewing Editor. The following individual involved in review of your submission has agreed to reveal their identity: Robert A Martienssen (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This report describes a forward genetic screen for Arabidopsis anti-silencers that identifies the protein LIL, which through yeast 2-hybrid analysis leads to the finding that MBD7 and associated factors are required for the expression of two luciferase reporter transgenes. Several papers have recently been published on MBD7, which concluded that it functions to promote DNA demethylation. The data presented here lead to a very different conclusion, that MBD7 does not promote DNA demethylation. Although this paper does not determine how the MBD7 complex is affecting transgene expression, it was felt that this study brings compelling evidence for a new mechanism of the MBD7-LIL complex in transgene regulation.

The Reviewing Editor and other reviewers are generally interested in your work and find the study of significant importance to be suitable for publication in *eLife*. However, the consensus among the reviewers is that the following aspects of the paper must be strengthened before we proceed further.

Essential revisions:

Below are the points that should be addressed upon revision. Point 1 is a required experiment, and Point 2 is a suggested experiment. Points 3-11 may require textual changes and/or additional analyses, but should not require additional experimental evidence. Whether or not you agree with a point, please address it in a point-by-point response.

1\) Does MBD7 bind to the methylated promoter of the reporter gene? A ChIP-qPCR experiment would confirm that.

2\) It is suggested that you choose candidate genes that came up positive in ChIP in previous studies and assay for a mutant effect on expression in seed, where the MBD7 complex is highly expressed, and show that the effect is independent of methylation. However, given the complexity of seed tissue, we recognize that this kind of experiment might be challenging to interpret.

3\) Clarifications are needed for understanding what was done in the experiments described in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}.

4\) With respect to the insufficiency of d35S promoter 3\'-end hypermethylation to cause LUC gene silencing, the possibility needs to be considered that CHH methylation alone is sufficient to cause silencing.

5\) With respect to the inability of a LIL transgene not complementing the identified methylation differences, the arguments presented should take into account the partial complementation seen in [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}).

6\) Can downstream function of the MBD7 complex be distinguished from independent function? These distinct possibilities need to be explicitly discussed.

7\) Interaction affinities, if they have been determined experimentally, should be compared between the previously published Y2H analysis and the current one.

8\) Subtle changes in the transgene methylation might have gone undetected.

9\) Global misregulation of methylation caused by loss of the MBD7 complex might be detected by looking an increase in variation of methylation in the mutants.

10\) Could there be redundancy with other MBD-ACD proteins?

11\) Given the published results of MBD7 binding methylated genomic regions and influencing transcription at a similar time point as the one tested here, you should comment on these discrepancies.

*Reviewer \#1:*

This manuscript identifies MBD7 and associated factors as required for the expression of two LUC transgenes. Several papers have recently been published on the function of MBD7 and interacting proteins (Lang et al., 2015; Li et al., 2015; Want et al., 2015). These papers concluded that MBD7 functions at ROS1 targets to promote DNA demethylation. This is despite the fact that the overlap between *ros1 dml2 dml3* hypermethylated regions and *mbd7* hypermethylated regions is actually quite low. The data presented here are similar, but have the benefit of extensive replication. A very different conclusion is reached -- that MBD7 does not promote DNA demethylation. Although this paper does not determine how the MBD7 complex is affecting transgene expression, this is an important contribution to understanding the function (or excluding potential functions) of α-crystallin domain and MBD7 proteins.

Specific comments to address:

For the LUCH and YJ methylation profiles in [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, how were reads mapped to the nearly identical d35S sequences upstream of LUC and NPTII? How were 24nt sRNAs uniquely mapped? It is essential to know whether or not the LUC gene has promoter methylation, as the system is described as one where genes have high promoter methylation but are expressed. (This may be in the legend but it was cut-off.) This also applies to [Figure 4](#fig4){ref-type="fig"}. It seems that this is eventually addressed in [Figure 5](#fig5){ref-type="fig"} for YJ, but providing additional clarity in the main text is recommended. In [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} please also show the methylation profiles using uniquely-mapping reads only. It remains unclear whether LUCH has a hypermethylated promoter.

In the subsection "Genetic uncoupling of the hyper-methylation and LUC expression phenotypes at the YJ reporter" the authors conclude that hypermethylation of the 3\' end of the d35S promoter is not sufficient to cause LUC gene silencing. This is because *nrpe1* and *ago4* mutants are also hypermethylated, yet LUC expression is higher. *nrpe1* and *ago4* mutants only have higher methylation in the CG context, and have lower CHH methylation than the other genotypes. The counter-argument is that CHH methylation alone is sufficient to cause LUC gene silencing. The authors should modify this conclusion to be more inclusive of the data presented.

The arguments about a LIL transgene not complementing the identified methylation differences (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", third paragraph) are not fully convincing because the LIL transgene does not appear to fully complement the LUC expression phenotype ([Figure 6---figure supplement 3A/B](#fig6s3){ref-type="fig"}).

Why do the authors conclude that the MBD7 complex functions downstream of DNA methylation (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", last paragraph and others)? Functioning entirely independent of methylation seems as likely. Independence is occasionally mentioned, but seem to be used interchangeably with downstream in the text, when biologically these would seem to mean two very different things. Just because the YJ and LUCH transgenes are methylated does not mean that the complex exclusively regulates expression of methylated regions of the genome. There may be some other feature about these transgenes that causes the complex to act on them.

*Reviewer \#2:*

The study presented here reports a forward genetic screen for anti-silencing factors identifying LIL, an Arabidopsis gene also known as IDM3/IDL1. Through Y2H and Co-IP experiments, the authors recover the different interacting partners of LIL, highlighting a putative complex containing MBD7, ROS4/IDM1 and ROS5/IDM2. This particular complex is thought to participate in the recruitment of the ROS1 protein to DNA so it can excise methylated cytosine thereby promoting transcription (Lang et al., 2015; Li et al., 2015; Wang et al., 2015). The present work suggests that the MBD7-LIL complex promotes transgene transcription independently of any variation of DNA methylation, contrasting with previous studies. For this, the authors thoroughly examine the hyper-methylation phenotype of the mutants and conclude that it is inconsequential for the transgene silencing and barely significant genome-wide when comparing between replicates and controls. While this study brings compelling evidence for a new mechanism of the MBD7-LIL complex in transgene regulation, I would suggest the two following points be addressed before considering publications:

1\) Since the most important conclusion for this paper comes from two independent transgenes, it would be important to demonstrate the binding of MBD7 to the methylated promoters of at least one of these reporter genes. Since the authors already have introduced tagged versions of MBD7 in their YJ reporter line, a ChIP-qPCR could easily confirm a direct role for the complex in promoting transgene expression.

2\) A genome-wide ChIP experiment has revealed thousands of binding sites for MBD7 in transposable elements and genes (Lang et al., 2015). Yet in the present study, RNAseq experiment fails to identify any target in *mbd7* and *lil* mutants. To prove the biological relevance of their proposed methylation-independent promotion of transcription, it would be interesting to investigate changes in expression further. Since the genes involved in the MBD7 complex appear to have high expression in seed (according to eFP browser and genevestigator), targeted expression survey (based on loci identified in previous studies) could be conducted rapidly in these tissues for at least one mutant background. It would also be essential to show that the changes in expression are independent of DNA methylation changes.

*Reviewer \#3:*

Recent publications indicate that the MBD7 and IDM3 enhance transcription through demethylation. This manuscript present contradictory data that suggest these components instead activate transcription from methylated targets without altering methylation. While this alternative viewpoint is important to consider and the MethylC-seq analysis is very compelling, I am not convinced that the authors have ruled out alternative explanations. In particular, issues of redundancy between MBD-ACD complexes is not addressed, nor is there evidence for transcriptional activation of endogenous loci in the absence of MBD7-IDM3. As is often the case when attempting to argue against published conclusions, the data are extensive and complex, and might not be appropriate for a general scientific publication.

Major comments:

Because the MBD7d3 construct does contain a tiny overlap with the StkC domain, it remains possible that this bit of StkC is mediating interaction with IDM3. Since the MBD7-IDM3 interaction was previously mapped to the StkC domain with Y2H, the authors should include that construct in their analysis to directly compare interaction affinities.

Although MethylC-seq and Bisulfite/sanger sequencing indicate that there is little to no change in methylation of the YJ transgene, it remains possible that the subtle change in methylation of one small region is responsible for the observed change in transcription. Unfortunately, the *nrpe1* and *ago4* mutants do not completely rule out this possibility due to the possible \"compensatory effects\" that the authors acknowledge (subsection "Genetic uncoupling of the hyper-methylation and LUC expression phenotypes at the YJ reporter", last paragraph).

Is there the possibility that loss of the MBD7 complex causes misregulation of methylation such to increase variation in methylation across the genome? This could account for the large number of DMRs identified in each dataset that were not conserved between replicates. With so many control samples, it should be possible to determine the variation in the controls and compare it with the variation in the mutants to detect any possible increase in variation.

If the MBD7 complex functions as the authors suggest -- countering DNA methylation to allow transcription, then why aren\'t genes differentially expressed in the *lil* and *mbd7* backgrounds (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", third paragraph)? I\'m afraid that this might be a fatal flaw -- the assertion that MBD7 regulates transcription without changing methylation is based on a lack of changes in DNA methylation, but there is a similar lack of change in gene expression.

The authors offer no evidence that MBD-ACD don\'t function redundantly at most genomic loci, making it difficult to agree with the authors\' key conclusion at the end of the first paragraph of the subsection "The MBD7 complex and the DNA demethylation machinery".

10.7554/eLife.19893.035

Author response

*Essential revisions:*

*Below are the points that should be addressed upon revision. Point 1 is a required experiment, and Point 2 is a suggested experiment. Points 3-11 may require textual changes and/or additional analyses, but should not require additional experimental evidence. Whether or not you agree with a point, please address it in a point-by-point response.*

*1) Does MBD7 bind to the methylated promoter of the reporter gene? A ChIP-qPCR experiment would confirm that.*

To address this question we carried out numerous ChIP-qPCR and ChIP-seq experiments using different transgenic lines expressing tagged versions of MBD7 or LIL under the control of their endogenous promoters (e.g. pMBD7::MBD7-3xHA, pMBD7::MBD7-3xFlag, and pLIL::9xMyc-LIL). Despite extensive optimization of different experimental conditions (in vivo vs. in vitro crosslinking, Formaldehyde (FD) vs. ethylene glycol bis succinimidyl sussinate (EGS) +FD crosslinking, tissue quantities up to \~5 g, and several published ChIP protocols), no enrichment was observed either at the *YJ* reporter or at other genomic loci. However, using a previously published, GFP tagged MBD7 construct driven by a 35S promoter, we were able to observe modest, but consistent and reproducible enrichment of MBD7 at the *YJ* reporter, specifically at the methylated *d35S* promoter driving *LUC* expression. We have now added this data as [Figure 4E](#fig4){ref-type="fig"} and have added the following text to the Results section:

"As these findings reveal a correlation between the presence of a functional MBD7 complex and the DNA methylation status of the YJ reporter, several chromatin immunoprecipitation (ChIP) experiments were conducted to determine whether the MBD7 complex associates with this reporter. \[...\] Taken together, these methylation and ChIP analyses are consistent with the hyper-methylation phenotype observed in the methyl-cutting assays and suggest a direct role for the MBD7 complex in regulating expression at the *YJ* reporter."

*2) It is suggested that you choose candidate genes that came up positive in ChIP in previous studies and assay for a mutant effect on expression in seed, where the MBD7 complex is highly expressed, and show that the effect is independent of methylation. However, given the complexity of seed tissue, we recognize that this kind of experiment might be challenging to interpret.*

We thank the reviewer for this very nice suggestion, however as detailed below, we were not able to identify any target genes with altered gene expression in seeds.

As suggested, we collected a list of 23 candidate genes that were either shown to be mis-expressed or to be bound by MBD7 in previous publications. After testing each primer set on gDNA, RNA was extracted from dry seeds to make cDNA. Of the 23 candidate genes only 8 were expressed in dry seeds and none showed altered expression in *lil* and *mbd7* mutants.10.7554/eLife.19893.026Author response image 1.Expression of putative MBD7 targets in dry seeds.Quantification of transcript levels by RT-qPCR using pooled dry seeds. Transcript levels were normalized to *UBIQUITIN5* with the expression level of the target loci in the *YJ* and *LUCH* controls set to one. Error bars indicate the standard deviation from at least two biological replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.026](10.7554/eLife.19893.026)

*3) Clarifications are needed for understanding what was done in the experiments described in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"}.*

We thank the reviewers for calling this issue to our attention. We agree that it is important to know how multi-mapping reads are treated, and indeed had included statements addressing this point at the ends of [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Figure 4](#fig4){ref-type="fig"} legends, but the legend for [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} was cut off calling this issue to our attention. The following statement is now present in both legends "Note that two *d35S* promoters driving *LUC* and *NPTII* are 94% identical in sequence, thus the DNA methylation data includes both multi-mapping and unique reads".

We have also made this point more clear in the Methods, under the "MethylC-seq analysis at the *YJ* and *LUCH* transgenes" section, by including the following sentence: "Since the *d35S* promoters driving the expression of the *LUC* and *NPTII* genes are 94% identical, both unique and multi-mapping reads were included, with the maximum number of equal best hits set to 2 (-w 2)."

In addition, as suggested by reviewer 1, we have also included in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} the DNA methylation and 24nt siRNA profiles allowing only uniquely mapped reads. Along with this new data, we have added the necessary information to the Methods section and to [Supplementary files 1](#SD3-data){ref-type="supplementary-material"} and [2](#SD4-data){ref-type="supplementary-material"}.

Finally, as also suggested by reviewer 1, we further altered the main text in two places to further clarify issues posed by the 94% identical *d35S* promoters. First, in the section describing the characterization of the two reporters, we made the following alteration:

"Given the known role of DNA methylation in regulating *LUC* expression at the *LUCH* reporter \[Won et al., 2012\], the DNA methylation and siRNA profiles for both *LUCH* and *YJ* reporters were determined by MethylC-sequencing (MethylC-seq) and small RNA sequencing (smRNA-seq), respectively ([Supplementary file 1A-D](#SD3-data){ref-type="supplementary-material"}), allowing either multi-mapping ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) or unique reads ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"})."

Second, in the section detailing the traditional bisulfite sequencing, we made the following alteration to emphasize that such analysis is required to assess the methylation specifically at the *d35S* promoter driving *LUC* expression, independently of both the 94% identical *d35S* promoter driving *NPTII* expression in the YJ transgene and similar *d35S* promoters in the T-DNA mutant lines.

"Thus, to specifically assess DNA methylation at the *d35S* promoter driving the *LUC* gene, without interference from the 94% identical *d35S* promoter driving *NPTII* expression ([Figure 1---figure supplement 1C,E](#fig1s1){ref-type="fig"}) or the similar *d35S* promoters present in the T-DNA insertion mutant backgrounds, traditional bisulfite conversion assays coupled with Sanger sequencing were conducted."

"These findings demonstrate that the two methods of bisulfite sequencing are comparable and, unlike the MethylC-seq data ([Figure 1---figure supplement 1C,E](#fig1s1){ref-type="fig"}), definitively show that the changes in DNA methylation observed in the *lil* and *mbd7* mutants occur at the *35S* promoter driving *LUC* expression."

*4) With respect to the insufficiency of d35S promoter 3\'-end hypermethylation to cause LUC gene silencing, the possibility needs to be considered that CHH methylation alone is sufficient to cause silencing.*

We agree that this is an important point. Thus, we have modified the main text to soften our conclusion, as shown below, and have included a more detailed visual representation of the traditional bisulfite sequencing using cymate, which we hope will aid in the data interpretation. However, we would like to raise the point that if CHH methylation alone was enough to account for all the gene silencing, then one would expect higher LUC expression in the *YJ nrpe1* and *YJ ago4* backgrounds as compared to the YJ control, which is not what we observed. Thus, a more complicated compensatory model would need to be invoked.

"While compensatory effects on gene expression due to decreased non-CG methylation at other regions of the *d35S* promoter in the *ago4* and *nrpe1* mutants cannot be fully excluded, these findings suggest that the hyper-methylation at the 3' end of the *d35S* promoter region alone is not sufficient to cause gene silencing."

"Secondly, we demonstrated that hyper-methylation at the 3' end of the *d35S* promoter in the *YJ* reporter does not appear to be sufficient to cause gene silencing ([Figure 5](#fig5){ref-type="fig"}). As such, the MBD7 complex joins a small number of factors including MOM1, MORC1, MORC6, ATXR5, and ATXR6, that can act primarily downstream of DNA methylation."

"Furthermore, we found that while mutations in components of the MBD7 complex led to increased DNA methylation at the d35S promoter driving LUC expression, this methylation alone did not appear to be sufficient to cause LUC silencing."

"Conversely, all three mutants (*ago4-6, nrpe1-11* and *rdd*) showed a hyper-methylation phenotype similar to that observed in the *lil* and *mbd7* mutants at the 3' end of the *35S* promoter ([Figure 5A, B](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"})."

*5) With respect to the inability of a LIL transgene not complementing the identified methylation differences, the arguments presented should take into account the partial complementation seen in [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}).*

We agree that the level of complementation should be taken into account when interpreting the MethylC-seq data. Therefore, we have added the following sentence to the main text.

"In general, the complementing lines more closely resemble the *YJ lil-1_r7* mutant line than the *YJ_r7* control ([Figure 6C](#fig6){ref-type="fig"}), suggesting minimal complementation overall. Although the possibility of partial complementation at some loci cannot be excluded, even at the most robust set of DMRs, only 1 of 33 DMRs returned to control levels of DNA methylation ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}, hyper-CHH site 1)."

*6) Can downstream function of the MBD7 complex be distinguished from independent function? These distinct possibilities need to be explicitly discussed.*

We thank the reviewers for pointing out that we were not clear enough in our usages of the terms "downstream" and "independent". Based on the 5 AZA experiments presented in [Figure 3](#fig3){ref-type="fig"} we have shown that, at least at the *YJ* and *LUCH* transgenes, the anti-silencing functions of the MBD7 complex are dependent on DNA methylation (i.e. expression is only lower in the *mbd7* and *lil* mutants when methylation is present). Thus, we conclude that they act downstream rather than independently of DNA methylation at these loci. However, in several other places in the main text we state that the MBD7 complex function/acts in a manner that is "largely independent of changes in DNA methylation". In hindsight, we now appreciate that this caused confusion, and have reworded the following statements for clarity.

"Given the absence of endogenous targets transcriptionally regulated by the MBD7 complex, it is likely that this complex functions redundantly with other MBD-ACD complexes and/or is required only under specific conditions. Nonetheless, our findings demonstrate that this complex has the ability to regulate gene expression in a manner largely downstream of DNA methylation at *LUC* reporters."

"Rather than functioning as part of the DNA demethylation pathway, as has been previously hypothesized \[Lang et al., 2015; Li et al., 2015; Wang et al., 2015\], our results suggest that the MBD7 complex functions in a manner largely downstream of DNA methylation. As very few proteins have been characterized that function downstream of DNA methylation, further characterization of this complex...".

"Further support for the notion that the primary function of the MBD7 complex is downstream of DNA methylation comes from a comparison of the reporter transgenes used to identify components of this complex."

*7) Interaction affinities, if they have been determined experimentally, should be compared between the previously published Y2H analysis and the current one.*

We have not determined interaction affinities.

*8) Subtle changes in the transgene methylation might have gone undetected.*

We agree that we cannot exclude the possibility that subtle changes in methylation could play important roles in regulating gene expression. To further address this question we have now taken the suggestion of reviewer 2 and added a visual representation of all the traditional bisulfite sequencing as a new figure ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Providing this data should make it easier to interpret the data presented here and aid in future re-analysis of the data as the field progresses and we gain a deeper understanding of how DNA methylation controls gene expression.

*9) Global misregulation of methylation caused by loss of the MBD7 complex might be detected by looking an increase in variation of methylation in the mutants.*

We thank the reviewer for raising this interesting point. However, as there are many ways to both define and assess variation in methylation, this is a quite difficult question to definitively address. To begin addressing this question, we did investigate the variation in the control vs experimental samples by looking at the variation in the number of DMRs amongst the sample sets. The data is plotted below:10.7554/eLife.19893.027Author response image 2.Investigation into variation in DNA methylation.Comparisons of the average number of DMRs observed between all pairwise combinations of three YJ replicates (YJ_r1, YJ_r5 and YJ_r7) or between all pairwise combinations of these controls and their corresponding YJ_lil data sets. Error bars represent the standard deviation as a measure of variance.**DOI:** [http://dx.doi.org/10.7554/eLife.19893.027](10.7554/eLife.19893.027)

While the variance (std dev error bars) seems to be similar between the wildtype and mutant comparisons in all cases, suggesting there is no increase in the methylation variation in the mutants, we cannot confidently say whether there are statistically significant differences because our sample size is too small to determine whether or not the DMR numbers follow a particular distribution from which p values can be determined. Thus, we feel it would be premature to make statements regarding methylation variation based on our current datasets. This is especially true as no proteins or pathways have been identified that serve to increase the variation in methylation patterns and thus the burden of proof for such a claim would be very high.

*10) Could there be redundancy with other MBD-ACD proteins?*

We agree with the assessment that MBD-ACD proteins/complexes could function redundantly when it comes to regulating endogenous loci and thank the reviewers for calling to our attention that we should emphasize this more clearly in the manuscript. In its original form, this possibility was mentioned twice in the Discussion, but not mentioned in the Results section. We have now edited and/or added the following statements in the Results to more clearly acknowledge the possibility of redundant functions between the various MBD and ACD proteins at endogenous loci.

"Thus, although there are clear genetic connections between MBD7, LIL and ROS1 in the regulation of several transgenic reporters \[Lang et al., 2015; Li et al., 2015; Wang et al., 2015\], as a general rule, the demethylation pathway does not appear to function in a manner that depends solely on either MBD7 or LIL."

"Given the absence of endogenous targets transcriptionally regulated by the MBD7 complex, it is likely that this complex functions redundantly with other MBD-ACD complexes and/or is required only under specific conditions. Nonetheless, our findings demonstrate that this complex has the ability to regulate gene expression in a manner largely downstream of DNA methylation at LUC reporters."

"Thus, while we cannot fully rule out a role for the MBD7 complex as a highly locus-specific regulator of the DNA demethylation pathway, nor do we know the extent to which other MBD-ACD complexes might function redundantly with the MBD7 complex and mask its role at endogenous targets and/or connections with the demethylase machinery, we currently favor a model based on our extensive transgene analysis in which the MBD7 complex functions largely downstream of DNA methylation to promote gene expression through a yet unknown mechanism."

*11) Given the published results of MBD7 binding methylated genomic regions and influencing transcription at a similar time point as the one tested here, you should comment on these discrepancies.*

To address this comment we have now added a new supplemental figure ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}) and a separate section to the Results in which we provide additional details regarding our RNAseq data and also draw comparisons with the genes identified in previous studies. See below:

"Transcriptome profiling of *mbd7* and *lil* mutants

To further investigate the role of the MBD7 complex in gene regulation, we assessed the effects of the *lil* and *mbd7* mutants on gene expression by transcriptome profiling. \[...\] However, perhaps differences in growth conditions and/or the differing sensitivities and normalization procedures of the assays used to assess gene expression levels (i.e. mRNA-seq vs qPCR), as well as the already low expression levels of the downregulated genes under our conditions, represent contributing factors ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"})."

*Reviewer \#1:*

*\[...\] Specific comments to address:*

*For the LUCH and YJ methylation profiles in [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}, how were reads mapped to the nearly identical d35S sequences upstream of LUC and NPTII? How were 24nt sRNAs uniquely mapped? It is essential to know whether or not the LUC gene has promoter methylation, as the system is described as one where genes have high promoter methylation but are expressed. (This may be in the legend but it was cut-off.) This also applies to [Figure 4](#fig4){ref-type="fig"}. It seems that this is eventually addressed in [Figure 5](#fig5){ref-type="fig"} for YJ, but providing additional clarity in the main text is recommended. In [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} please also show the methylation profiles using uniquely-mapping reads only. It remains unclear whether LUCH has a hypermethylated promoter.*

As detailed in Essential revisions point 3, we have now included data showing methylation and siRNA levels at the YJ and LUCH reporters using only uniquely mapping reads and have further clarified the main text.

*In the subsection "Genetic uncoupling of the hyper-methylation and LUC expression phenotypes at the YJ reporter" the authors conclude that hypermethylation of the 3\' end of the d35S promoter is not sufficient to cause LUC gene silencing. This is because nrpe1 and ago4 mutants are also hypermethylated, yet LUC expression is higher. nrpe1 and ago4 mutants only have higher methylation in the CG context, and have lower CHH methylation than the other genotypes. The counter-argument is that CHH methylation alone is sufficient to cause LUC gene silencing. The authors should modify this conclusion to be more inclusive of the data presented.*

As detailed in Essential revisions point 4, we have amended the text to address this point.

*The arguments about a LIL transgene not complementing the identified methylation differences (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", third paragraph) are not fully convincing because the LIL transgene does not appear to fully complement the LUC expression phenotype ([Figure 6---figure supplement 3A/B](#fig6s3){ref-type="fig"}).*

As detailed in Essential revisions point 5, we have altered the main text to include the possibility that there could be some partial complementation.

*Why do the authors conclude that the MBD7 complex functions downstream of DNA methylation (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", last paragraph and others)? Functioning entirely independent of methylation seems as likely. Independence is occasionally mentioned, but seem to be used interchangeably with downstream in the text, when biologically these would seem to mean two very different things. Just because the YJ and LUCH transgenes are methylated does not mean that the complex exclusively regulates expression of methylated regions of the genome. There may be some other feature about these transgenes that causes the complex to act on them.*

As detailed in Essential revisions point 6, the 5 aza experiments in [Figure 3](#fig3){ref-type="fig"} show that the function of the MDB7 complex is dependent on the presence of DNA methylation. This finding, along with the DNA methylation analyzes showing minimal changes in DNA methylation in the *mbd7* and *lil* mutants, lead us to conclude that the MBD7 complex functions largely downstream of DNA methylation. We have modified the main text as necessary to avoid confusion cause by use of the phrase "independent of changes in DNA methylation".

*Reviewer \#2:*

*\[...\] While this study brings compelling evidence for a new mechanism of the MBD7-LIL complex in transgene regulation, I would suggest the two following points be addressed before considering publications:*

*1) Since the most important conclusion for this paper comes from two independent transgenes, it would be important to demonstrate the binding of MBD7 to the methylated promoters of at least one of these reporter genes. Since the authors already have introduced tagged versions of MBD7 in their YJ reporter line, a ChIP-qPCR could easily confirm a direct role for the complex in promoting transgene expression.*

As detailed in Essential revisions point 1, we have added MBD7-GFP ChIP-qPCR data showing enrichment of this protein at the *YJ* reporter as [Figure 4E](#fig4){ref-type="fig"}.

*2) A genome-wide ChIP experiment has revealed thousands of binding sites for MBD7 in transposable elements and genes (Lang et al., 2015). Yet in the present study, RNAseq experiment fails to identify any target in mbd7 and lil mutants. To prove the biological relevance of their proposed methylation-independent promotion of transcription, it would be interesting to investigate changes in expression further. Since the genes involved in the MBD7 complex appear to have high expression in seed (according to eFP browser and genevestigator), targeted expression survey (based on loci identified in previous studies) could be conducted rapidly in these tissues for at least one mutant background. It would also be essential to show that the changes in expression are independent of DNA methylation changes.*

As detailed in Essential revisions point 2, we were unable to show altered expression of candidate MBD7 targets in seeds from *lil* and *mbd7* mutants.

*Reviewer \#3:*

*\[...\] Because the MBD7d3 construct does contain a tiny overlap with the StkC domain, it remains possible that this bit of StkC is mediating interaction with IDM3. Since the MBD7-IDM3 interaction was previously mapped to the StkC domain with Y2H, the authors should include that construct in their analysis to directly compare interaction affinities.*

While we agree that this is possible, it seems unlikely given the limited overlap (only 11 amino acids), which is why in the main text we stated that our findings "...suggesting that the interaction between MBD7 and LIL can be mediated by several regions of the MBD7 protein...".

*Although MethylC-seq and Bisulfite/sanger sequencing indicate that there is little to no change in methylation of the YJ transgene, it remains possible that the subtle change in methylation of one small region is responsible for the observed change in transcription. Unfortunately, the nrpe1 and ago4 mutants do not completely rule out this possibility due to the possible \"compensatory effects\" that the authors acknowledge (subsection "Genetic uncoupling of the hyper-methylation and LUC expression phenotypes at the YJ reporter", last paragraph).*

As detailed in Essential revisions point 8, we agree that we cannot exclude the possibility that subtle changes in methylation could play important roles in regulating gene expression and have included a more detailed representation of our DNA methylation data ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) to help address this issue.

*Is there the possibility that loss of the MBD7 complex causes misregulation of methylation such to increase variation in methylation across the genome? This could account for the large number of DMRs identified in each dataset that were not conserved between replicates. With so many control samples, it should be possible to determine the variation in the controls and compare it with the variation in the mutants to detect any possible increase in variation.*

As detailed in Essential revisions point 9, we feel it would be premature to make statements regarding methylation variation based on our current datasets and level of statistical expertise.

*If the MBD7 complex functions as the authors suggest -- countering DNA methylation to allow transcription, then why aren\'t genes differentially expressed in the lil and mbd7 backgrounds (subsection "Genome-wide profiling shows that MBD7 and LIL have minimal effects on DNA methylation", third paragraph)? I\'m afraid that this might be a fatal flaw -- the assertion that MBD7 regulates transcription without changing methylation is based on a lack of changes in DNA methylation, but there is a similar lack of change in gene expression.*

As detailed in Essential revisions point 10, we feel that redundancy with in MBD and LIL families could account for the lack of expression defects at endogenous loci and have modified the text as specified to make this point more clear.

*The authors offer no evidence that MBD-ACD don\'t function redundantly at most genomic loci, making it difficult to agree with the authors\' key conclusion at the end of the first paragraph of the subsection "The MBD7 complex and the DNA demethylation machinery".*

As detailed in Essential revisions point 10, we have now added a statement to the Results acknowledging that the MBD-ACD complexes may act redundantly at endogenous loci.

[^1]: National Academy of Agricultural Science, Rural Development Administration, Suwon, Republic of Korea.

[^2]: These authors contributed equally to this work.
